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Summary 
 
RNA polymerase II (Pol II) is the eukaryotic enzyme responsible for transcribing protein-
coding genes into messenger RNA (mRNA). This thesis describes the study on the molecular 
mechanisms of Pol II interacting with DNA damages. The two damages investigated are 1,2-
d(GpG) DNA intrastrand cross-links (cisplatin lesions), induced by the anticancer drug 
cisplatin and 8-oxoguanine (8oxoG), the most encountered DNA lesion resulting from 
oxidative stress.  
We performed a structure-function analysis of Pol II stalling at a cisplatin lesion in the 
DNA template. Pol II stalling results from a translocation barrier that prevents delivery of the 
lesion to the active site. AMP misincorporation occurs at the barrier and also at an abasic site, 
suggesting that it arises from nontemplated synthesis according to an ‘A-rule’ known for DNA 
polymerases. Pol II can bypass a cisplatin lesion that is artificially placed beyond the 
translocation barrier, even in the presence of a G-A mismatch. Thus, the barrier prevents 
transcriptional mutagenesis.  
In addition, we combined structural and functional data to derive the molecular 
mechanism of Pol II transcription over 8oxoG. When Pol II encounters 8oxoG in the DNA 
template strand, it correctly incorporates cytosine in most instances, but it also 
misincorporates adenine. The misincorporated adenine forms a Hoogsteen base pair with 
8oxoG at the active center. This misincorporation requires rotation of the 8oxoG base from the 
standard anti- to an uncommon syn-conformation, which likely occurs during 8oxoG loading 
into the active site at a lower rate. X-ray analysis shows that the misincorporated adenine 
forms a Hoogsteen base pair with 8oxoG in the polymerase active center. Mass spectrometric 
analysis of RNA extension products shows that the misincorporated adenine escapes the 
intrinsic proofreading function of Pol II, and remains in the RNA product after polymerase 
bypass, resulting in transcriptional mutagenesis. Mutagenesis is suppressed by the transcript 
cleavage-stimulatory factor TFIIS, which is essential for cell survival during oxidative stress. 
Previously, the mechanism of Pol II stalling at a cyclobutane pyrimidine dimer 
photolesion was investigated by our group. In this thesis we show that the stalling mechanism 
at a cisplatin lesion differs from that of Pol II stalling at a photolesion, which allows delivery of 
the lesion to the active site but blocks transcription by lesion-templated misincorporation. In 
case of 8oxoG, no stalling occurs at all, which leads to transcriptional mutagenesis. Together, 
these results lead to the conclusion that it is impossible to predict the mechanisms of 
transcriptional stalling or mutagenesis at other types of lesions. 
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1 Introduction 
 
1.1 Eukaryotic mRNA transcription 
 
The process of DNA transcription into messenger RNA (mRNA) is catalyzed by DNA 
dependent RNA polymerases, and specifically in eukaryotes by RNA polymerase II (Pol II). 
The mRNA transcription cycle consists of three stages: initiation, elongation and termination. 
Initiation involves binding Pol II to the promoter, local melting, and forming the first few 
phosphodiester bonds. The initiation phase is subject to the most regulation. To allow 
initiation, appropriate modification of chromatin at the promoter region is essential (Li et al., 
2007). Pol II has then to be recruited to the promoter. In eukaryotes, the core promoter is the 
basis for the assembly of the transcription preinitiation complex (PIC). Additionally, regulatory 
factors, namely activators and repressors, bind to enhancer and silencer elements on the 
DNA respectively, to allow transmission of regulatory signals via the coactivators. The PIC 
comprises the general transcription factors (GTFs) TFIIA, TFIIB, TFIID, TFIIE, TFIIF, TFIIH, 
and Pol II (Thomas and Chiang, 2006). These factors function together to initiate transcription 
at the transcription start site (Figure 1.1). PIC formation begins with the binding of transcription 
factor TFIID to the TATA box via the TATA-binding protein (TBP) subunit, to the initiator (Inr) 
and/or to the downstream promoter element (DPE). The entry of other general transcription 
factors follows by one of two possible pathways; either a sequential assembly pathway or a 
preassembled RNA polymerase II holoenzyme pathway. The promoter-bound complex is 
sufficient for a basal level of transcription. However, general cofactors are required to transmit 
regulatory signals between gene-specific activators and the general transcription machinery in 
the case of regulated, activator-dependent transcription (Thomas and Chiang, 2006). There 
are three classes of general cofactors: the TBP-associated factors (TAFs), the Mediator, and 
the upstream stimulatory activity (USA)-derived positive cofactors and negative cofactor 1 
(Figure 1.1). Promoter activity in a gene-specific or cell-type-specific manner is usually 
adjusted by the independent or combined function of the general cofactors. After PIC 
formation, TFIIH phosphorylates serines 2 and 5 in the CTD of Pol II and this process is 
stimulated by TFIIE. During the shift from initiation to elongation, phosphorylation on serine 5 
of the CTD is lost (Weaver, 2008). 
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Figure 1.1 The eukaryotic transcription machinery.  
General cofactors serve as molecular bridges in activator-dependent transcription. General 
cofactors (TAFs, Mediator, and USA) are required for transducing signals between gene-specific 
activators and components of the general transcription machinery. An activator normally 
contains a DNA-binding domain (DBD) contacting specific DNA sequences and an activation 
domain (AD) interacting with general cofactors or with components of the general transcription 
machinery. It should be noted that TAFs normally function as an integral part of TFIID, not as a 
free entity in mammalian cells as drawn here. Adopted from (Thomas and Chiang, 2006). 
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During elongation, Pol II polymerises ribonucleotides in the 5’→3’ direction to 
synthesize the remaining RNA. Transcription can also be controlled at the elongation level. 
TFIIS stimulates elongation by limiting arrest at discrete sites that produce a backtracked RNA 
that is extruded past the active site. It does this by inserting a hairpin loop into the active site 
of Pol II and stimulating an RNAse-activity that cleaves off the extruded 3’ end of the nascent 
RNA, which is causing transcription arrest. TFIIF also stimulates elongation, by limiting 
transient pausing (Weaver, 2008). 
Finally in termination, Pol II and the RNA product dissociate from the DNA template. 
An intact polyadenylation site and active factors that cleave at the polyadenylation site are 
required for transcription termination. Cleavage at the poly(A) site provides an entry site for 
the 5’→3’ exonuclease Rat1, which degrades the RNA until it catches the polymerase and 
terminates transcription (Weaver, 2008). 
 
1.2 Eukaryotic DNA-dependent RNA polymerases 
 
Gene transcription in eukaryotic cells is carried out by the three different DNA dependent RNA 
polymerases Pol I, Pol II, and Pol III. Pol I produces ribosomal RNA, Pol II synthesizes 
messenger RNAs and small nuclear RNAs, and Pol III produces transfer RNAs and other 
small RNAs. A fourth RNA polymerase, Pol IV, which was recently discovered in plants, is not 
included here, as its composition and structure are currently unknown. The RNA polymerases 
are multisubunit enzymes. Pol I, II, and III comprise 14, 12, and 17 subunits, and have a total 
molecular weight of 589, 514, and 693 kDa, respectively (Table 1.1). Ten subunits form a 
structurally conserved core, and additional subunits are located on the periphery.  
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Table 1.1 RNA polymerase subunits. 
RNA polymerase Pol I Pol II Pol III 
Ten-subunit core A190 Rpb1 C160 
 A135 Rpb2 C128 
 AC40 Rpb3 AC40 
 AC19 Rpb11 AC19 
 A12.2 Rpb9 C11 
 Rpb5 (ABC27) Rpb5 Rpb5 
 Rpb6 (ABC23) Rpb6 Rpb6 
 Rpb8 (ABC14.5) Rpb8 Rpb8 
 Rpb10 (ABC10α) Rpb10 Rpb10 
 Rpb12 (ABC10β) Rpb12 Rpb12 
Rpb4/7 subcomplex A14 Rpb4 C17 
 A43 Rpb7 C25 
TFIIF-like subcomplexa A49 (Tfg1/Rap74) C37 
 A34.5 (Tfg2/Rap30) C53 
Pol III-specific subcomplex – – C82 
 – – C34 
 – – C31 
Number of subunits 14 12 17 
aThe two subunits in Pol I and Pol III are predicted to form heterodimers that resemble part of the Pol II 
initiation/elongation factor TFIIF, which is composed of subunits Tfg1, Tfg2, and Tfg3 in 
Saccharomyces cerevisiae, and of subunits Rap74 and Rap30 in human. 
 
1.3 Structure of RNA polymerase II 
 
Pol II consists of a 10-subunit core enzyme and a peripheral heterodimer of subunits Rpb4 
and Rpb7 (Rpb4/7 subcomplex, Table 1.1). The core enzyme comprises subunits Rpb1, 
Rpb2, Rpb3, and Rpb11, which contain regions of sequence and structural similarity in Pol I, 
Pol III, bacterial RNA polymerases (Vassylyev et al., 2002; Zhang et al., 1999), and the 
archaeal RNA polymerase (Kusser et al., 2008). The Pol II core also comprises subunits 
Rpb5, Rpb6, Rpb8, Rpb10, and Rpb12, which are shared between Pol I, II, and III (common 
subunits, Table 1.1). Counterparts of these common subunits, except Rpb8, exist in the 
archaeal polymerase. But only a counterpart of Rpb6 exists in the bacterial enzyme (Minakhin 
et al., 2001). Finally, homologues of the core subunit Rpb9 exist in Pol I and Pol III, but not in 
the archaeal or bacterial enzyme.  
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Initial electron microscopic studies of Pol II revealed the overall shape of the enzyme 
(Darst et al., 1991). The core Pol II could subsequently be crystallized, leading to an electron 
density map at 6 Å resolution (Fu et al., 1999). Crystal improvement by controlled shrinkage 
and phasing at 3 Å resolution resulted in a backbone model of the Pol II core (Cramer et al., 
2000). This revealed that Rpb1 and Rpb2 form opposite sides of a positively charged active 
center cleft, whereas the smaller subunits are arrayed around the periphery. Refined atomic 
structures of the core Pol II were obtained in two different conformations and revealed 
domain-like regions within the subunits, as well as surface elements predicted to have 
functional roles (Cramer et al., 2001) (Figure 1.2 and Figure 1.3). The active site and the 
bridge helix, which spans the cleft, line a pore in the floor of the cleft. The Rpb1 side of the 
cleft forms a mobile clamp, which was trapped in two different open states in the free core 
structures (Cramer et al., 2001) but was closed in the structure of a core complex that 
included DNA and RNA (Gnatt et al., 2001). The mobile clamp is connected to the body of the 
polymerase by five switch regions that show conformational variability. The Rpb2 side of the 
cleft consists of the lobe and protrusion domains. Rpb2 also forms a protein wall that blocks 
the end of the cleft. 
The Pol II core structures lacked subunits Rpb4 and Rpb7, which can dissociate from 
the yeast enzyme (Edwards et al., 1991). A structure of the archaeal homologue of the Rpb4/7 
heterodimer showed that Rpb7 contains an N-terminal domain, later called the tip domain, and 
a C-terminal domain that includes an oligosaccharide-binding (OB) fold (Todone et al., 2001). 
The approximate location of Rpb4/7 on the core polymerase was first determined by electron 
microscopy (EM) of two-dimensional crystals (Jensen et al., 1998). Later, EM analysis of 
single particles revealed a closed clamp and showed that the Rpb4/7 subcomplex protrudes 
from outside the core enzyme below the clamp (Craighead et al., 2002). A different open-
closed transition that involved the polymerase jaws was observed by EM of two-dimensional 
crystals (Asturias et al., 1997). Crystallographic backbone models of the complete Pol II then 
revealed the exact position and orientation of Rpb4/7 and showed that it formed a wedge 
between the clamp and the linker to the unique tail-like C-terminal repeat domain (CTD) of 
Rpb1 (Armache et al., 2003; Bushnell and Kornberg, 2003). The crystal structure of free 
Rpb4/7 (Figure 1.2d), together with an improved resolution of the complete Pol II crystals, 
finally enabled refinement of a complete atomic model of Pol II (Armache et al., 2005) (Figure 
1.2b). 
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Figure 1.2 RNA polymerase structures.  
(a) Pol I hybrid structure (47).  
(b) Ribbon model of the refined complete Pol II crystal structure (Armache et al., 2005).  
(c) Pol III EM structure (Fernandez-Tornero et al., 2007) with the Pol II-based homology model 
and the crystal structure of C17/25 (Jasiak et al., 2006) fitted as published (Fernandez-Tornero et 
al., 2007).  
(d) Rpb4/7 subcomplex structures: A14/43 (left), Rpb4/7 (center) (Armache et al., 2005), C17/25 
(right). Adopted from (Cramer et al., 2008). 
 
The CTD of Rpb1 is flexible and consists of heptapeptide repeats of the consensus 
sequence YSPTSPS. The CTD integrates nuclear events by binding proteins involved in 
mRNA biogenesis (for reviews see References (Buratowski, 2003; Hirose and Manley, 2000; 
Meinhart et al., 2005)). CTD-binding proteins recognize a specific CTD phosphorylation 
pattern, which changes during the transcription cycle. Structural and functional studies of 
CTD-binding and CTD-modifying proteins and their complexes with CTD peptides elucidated 
CTD structure and revealed some of the mechanisms underlying CTD function. 
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Figure 1.3 Structure of the Pol II elongation complex (EC).  
(a) Overview of the EC structure (Kettenberger et al., 2004; Wang et al., 2006; Westover et al., 
2004).  
(b) Superposition of NTP-binding sites [red, insertion site; violet, entry site (Kettenberger et al., 
2004; Wang et al., 2006; Westover et al., 2004); pink, inactive preinsertion-like state 
(Kettenberger et al., 2004; Wang et al., 2006; Westover et al., 2004).  
(c) Functional Pol II surface elements in the EC. 
 
1.4 The Pol II elongation complex and nucleotide incorporation 
 
During the elongation phase of transcription, the polymerase moves along a DNA template 
and synthesizes a complementary chain of ribonucleotides. RNA extension begins with 
binding of a nucleoside triphosphate (NTP) substrate to the transcription elongation complex 
(EC) that is formed by the polymerase, DNA, and RNA. Catalytic addition of the nucleotide to 
the growing RNA 3’ end then releases a pyrophosphate ion. Finally, translocation of DNA and 
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RNA frees the substrate site for binding of the next NTP. The EC is characterized by an 
unwound DNA region, the transcription bubble. The bubble contains a short hybrid duplex 
formed between the DNA template strand and the RNA product emerging from the active site. 
The mechanism of RNA elongation was elucidated by structural studies of Pol II-nucleic acid 
complexes (Figure 1.3). EM first revealed the point of DNA entry to the Pol II cleft (Poglitsch et 
al., 1999). The first crystal structure of a Pol II–nucleic acid complex which was elucidated 
was that of the core Pol II transcribing a tailed template DNA (Gnatt et al., 2001), this template 
allows for promoter-independent transcription initiation. This structure revealed downstream 
DNA entering the cleft and an 8 to 9 base pair DNA-RNA hybrid in the active center. 
Comparison with the high-resolution core Pol II structure (Cramer et al., 2001) revealed 
protein surface elements predicted to play functional roles. Later, polymerase EC structures 
utilized synthetic DNA-RNA scaffolds (Kettenberger et al., 2004; Westover et al., 2004) and 
revealed the exact location of the downstream DNA and several nucleotides upstream of the 
hybrid. Mechanisms were suggested for how Pol II unwinds downstream DNA and how it 
separates the RNA product from the DNA template at the end of the hybrid. Although Pol II 
generally uses DNA as a template, there is also evidence that Pol II can use RNA templates. 
Recent structures showed that an RNA template-product duplex can bind to the site normally 
occupied by the DNA-RNA hybrid and provided the structural basis for the phenomenon of 
RNA dependent RNA synthesis by Pol II (Lehmann et al., 2007). 
Additional structures of Pol II ECs included the NTP substrate (Kettenberger et al., 
2004; Wang et al., 2006; Westover et al., 2004). These studies suggested how Pol II selects 
the correct NTP and how it incorporates a nucleotide into RNA. The NTP was 
crystallographically trapped in the insertion site (Wang et al., 2006; Westover et al., 2004), 
which is apparently occupied during catalysis, but a separate study also revealed the NTP in 
an overlapping, slightly different location, suggesting an inactive NTP-bound preinsertion state 
of the enzyme (Kettenberger et al., 2004). Both NTPs form Watson-Crick interactions with a 
base in the DNA template strand. Binding of the NTP to the insertion site involves folding of 
the trigger loop (Wang et al., 2006), a mobile part of the active center first observed in free 
bacterial RNA polymerase (Vassylyev et al., 2002), and in the Pol II-TFIIS complex 
(Kettenberger et al., 2003). Folding of the trigger loop closes the active site and may be 
involved in selection of the correct NTP. The NTP complex structures revealed contacts of the 
nucleotide with the polymerase, which explain discrimination of ribonucleotides against 
deoxyribonucleotides, and provided insights into the selection of the correct nucleotide 
complementary to the templating DNA base. Catalytic nucleotide incorporation apparently 
follows a two-metal ion mechanism suggested for all polymerases (Steitz, 1998). The Pol II 
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active site contains a persistently bound metal ion (metal A) and a second, mobile metal ion 
(metal B) (Cramer et al., 2001). Metal A is held by three invariant aspartate side chains and 
binds the RNA 3’ end (Cramer et al., 2001), whereas metal B binds the NTP triphosphate 
moiety (Westover et al., 2004). Recent studies of functional complexes of the bacterial RNA 
polymerase revealed the close conservation of the EC structure (Vassylyev et al., 2007a) and 
provided additional insights into nucleotide incorporation (Vassylyev et al., 2007b). As for Pol 
II, NTP binding to the insertion site can induce folding of the trigger loop. In the presence of 
the antibiotic streptolydigin, however, the NTP binds in the inactive, preinsertion state, in 
which the triphosphate and metal B are too far from metal A to permit catalysis. This finding 
supported a two step mechanism of nucleotide incorporation (Kettenberger et al., 2004; 
Vassylyev et al., 2007b). The NTP would first bind in the inactive preinsertion state to an open 
active center conformation. Complete folding of the trigger loop then leads to closure of the 
active center, delivery of the NTP to the insertion site, and catalysis. An alternative model for 
nucleotide addition involves binding of the NTP to a putative entry site in the pore, in which the 
nucleotide base is oriented away from the DNA template, and rotation of the NTP around 
metal ion B directly into the insertion site (Westover et al., 2004). 
 
1.5 Overcoming obstacles during elongation 
 
During active transcription, Pol II must overcome intrinsic DNA arrest sites, which are 
generally rich in A-T base pairs and pose a natural obstacle to transcription. At such sites, Pol 
II moves backward along DNA and RNA, resulting in extrusion of the RNA 3’ end through the 
polymerase pore beneath the active site and transcriptional arrest. The RNA cleavage 
stimulatory factor TFIIS can rescue an arrested polymerase by creating a new RNA 3’ end at 
the active site from which transcription can resume. The mechanism of TFIIS function was 
elucidated with the structures of Pol II and a Pol II EC in complex with TFIIS (Kettenberger et 
al., 2003, 2004). TFIIS inserts a hairpin into the polymerase pore and complements the active 
site with acidic residues, changes the enzyme conformation, and repositions the RNA 
transcript (Kettenberger et al., 2003, 2004). These studies supported the idea that the Pol II 
active site is tunable, as it can catalyze different reactions, including RNA synthesis and RNA 
cleavage (Kettenberger et al., 2003; Sosunov et al., 2003). 
Other obstacles to transcription are bulky lesions in the DNA template strand. Structural 
studies of Pol II ECs that contain a lesion in the template strand unraveled the mechanism of 
polymerase stalling at a bulky lesion, a UV light-induced thymine-thymine cyclobutane 
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pyrimidine dimer (CPD) (Brueckner et al., 2007). Cells efficiently eliminate CPDs by 
transcription-coupled DNA repair (TCR), which begins with Pol II stalling at the lesion. TCR 
continues with assembly of the nucleotide excision repair machinery, removal of a lesion-
containing DNA fragment, and repair of the resulting DNA gap. The structural studies revealed 
that the structure of the EC is generally not influenced by the presence of the lesion, except 
for some changes in the downstream DNA, arguing against allosteric models for the assembly 
of the repair machinery during TCR. The study also demonstrated a translocation barrier that 
impairs delivery of the CPD to the active site. This study also showed that Pol II can, under 
certain artificial conditions, bypass a distorting CPD lesion. 
 
1.6 Transcriptional mutagenesis 
 
When DNA damage is located in transcribed regions of the genome, RNA polymerase can 
stall, leading to TCR, or RNA polymerase can continue transcribing its product past a lesion 
(Figure 1.4), in this case mistakes may be introduced. If mistakes are introduced, for example 
by a miscoding or non-informational damage-site, transcriptional mutagenesis can occur. 
Furthermore, analysis of the miscoding properties of many lesions indicate that they will 
miscode similarly during both replication and transcription (Viswanathan et al., 1999). 
Transcriptional mutagenesis that is induced by DNA damage can in principle generate a pool 
of mutant mRNAs that could result in the production of mutant proteins that would alter the 
cellular phenotype (Figure 1.5). These mutant proteins might give the cell a growth advantage, 
or the ability to escape growth suppression, and the ensuing DNA replication past the lesion 
could convert it into a heritable mutation, giving rise to a mutant cell population now 
permanently expressing this advantageous protein (Saxowsky and Doetsch, 2006). This 
process has been called retromutagenesis since a transcriptional event could lead to a 
permanent DNA sequence change (Viswanathan and Doetsch, 1998). In nonproliferating 
cells, the contribution of transcriptional mutagenesis to the mutant protein pool, is likely to be 
much more apparent, because the capacities of certain DNA repair pathways are diminished 
in nondividing cells (Saxowsky and Doetsch, 2006). 
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Figure 1.4 Transcriptional encounters with DNA damage: What are the options?  
The presence of a lesion in the transcribed strand may cause different transcription outcomes 
depending on whether the lesion transiently pauses or permanently arrests the elongating 
polymerase. Adopted from (Tornaletti, 2009). 
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Figure 1.5 Transcriptional mutagenesis.  
Transcription past a DNA lesion (yellow box) with altered base pairing properties may lead to 
the production of a population of mutant transcripts. These transcripts can, in turn, be 
translated into mutant proteins that could alter the phenotype of the cell. Adopted from 
(Saxowsky and Doetsch, 2006). 
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1.7 Scope of this work 
 
Prior to this work, the mechanisms of recognition and bypass of CPD DNA lesions was 
analyzed (Brueckner et al., 2007). However, at that point it was unknown whether the 
mechanisms of transcriptional stalling or mutagenesis at other types of lesions could be 
predicted from this study. In addition, it was unknown whether transcriptional mutagenesis 
could occur at other lesions. To further elucidate these issues, the scope of this work was to 
introduce different lesions, specifically cisplatin and 8-oxoguanine, into the DNA template 
strand at several positions around the polymerase active site and to study the resulting Pol II 
ECs. This was achieved structurally, by solving the structure of Pol II in complex with these 
lesions, and functionally, by performing RNA elongation and cleavage assays. Together the 
mechanism of DNA damage recognition and the mechanism of transcriptional mutagenesis 
can be obtained. 
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2 Mechanism of transcriptional stalling at cisplatin-damaged DNA 
 
2.1 Introduction 
 
Cisplatin (cis-diamminedichloroplatinum(II)) is a widely used anticancer drug that forms DNA 
adducts that interfere with replication and transcription (Wang and Lippard, 2005). The most 
frequent cisplatin DNA adducts are 1,2-d(GpG) intrastrand cross-links, or cisplatin lesions, in 
which platinum coordinates the N7 atoms of adjacent guanosines in a DNA strand (Kartalou 
and Essigmann, 2001) (Figure 2.1). A cisplatin lesion in the DNA template strand blocks 
transcription elongation by the single-subunit RNA polymerase from phage T7 (Jung and 
Lippard, 2003) and by Pol II (Corda et al., 1991, 1993; Tornaletti et al., 2003), and leads to 
stable polymerase stalling (Jung and Lippard, 2006). The stalled Pol II elongation complex 
can be bound by the elongation factor TFIIS, which stimulates polymerase back-tracking and 
3’ RNA cleavage (Tornaletti et al., 2003). A small fraction of polymerases can apparently read 
through a cisplatin lesion (Tornaletti et al., 2003). The detailed molecular mechanisms of 
cisplatin DNA adduct processing by nucleic acid polymerases are not understood. Here we 
have used a combination of X-ray crystallography and RNA-extension assays to derive the 
molecular mechanism of Saccharomyces cerevisiae Pol II stalling at a cisplatin lesion. 
Comparison of the results with our previous analysis of Pol II stalling at a DNA photolesion, a 
TT cyclobutane pyrimidine dimer (Brueckner et al., 2007) (CPD, Figure 2.1), reveals that the 
two types of dinucleotide lesions trigger transcriptional stalling by different mechanisms.  
 
Figure 2.1 Structure of the 1,2-d(GpG) cisplatin lesion and the thymine-thymine CPD 
photolesion. 
GG cisplatin lesion TT photolesion 
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Figure 2.2 Structure of a cisplatin-damaged Pol II elongation complex.  
(a) Nucleic acid scaffolds. The color code is indicated and used throughout. Filled circles 
denote nucleotides with interpretable electron density that were included in the structure in C. 
Open circles denote nucleotides with non-interpretable or lacking electron density.  
(b) Structure of nucleic acids in Pol II elongation complex A. The final 2Fo-Fc electron density 
map is shown for the nucleic acids (blue, contoured at 1.0σ). The anomalous difference Fourier 
map reveals the location of the platinum atom (magenta, contoured at 15σ).  
(c) Overview of the cisplatin-damaged Pol II EC. Pol II is shown as a ribbon model in silver, with 
the bridge helix in green. The nucleic acids are in color, and the cisplatin lesion is shown as a 
stick model in orange.  
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2.2 Results 
 
2.2.1 Structure of a cisplatin-damaged Pol II elongation complex 
 
To elucidate recognition of cisplatin-induced DNA damage by transcribing Pol II, we carried 
out a structure-function analysis of elongation complexes containing a cisplatin lesion in the 
template DNA strand. Elongation complexes were reconstituted from the 12-subunit S. 
cerevisiae Pol II and nucleic acid scaffolds as described (Brueckner et al., 2007; Kettenberger 
et al., 2004). A cisplatin lesion was first incorporated at registers +2/+3 of the template strand, 
directly downstream of the NTP-binding site at register +1 (scaffold A, Figure 2.2a). The 
crystal structure of the resulting cisplatin-damaged elongation complex (complex A) was 
determined at 3.8  resolution (Figure 2.2b,c, Table 2.1 and Methods). A very strong peak in 
the anomalous difference Fourier map revealed the location of the platinum atom (Figure 
2.2b).  
 
Figure 2.3 Cisplatin-induced changes in the downstream DNA.  
Comparison of the course of nucleic acids in complex A (pale green) with that in the structures 
of the CPD-containing complexes B and C (Brueckner et al.) (violet and light blue, respectively). 
The proteins were superimposed based on the active site region and then omitted. 
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In the damaged elongation complex structure, the cisplatin lesion is bound at positions +2/+3, 
above the polymerase bridge helix (Figure 2.2b). The DNA-RNA hybrid occupies the upstream 
positions –1 to –8. The hybrid structure is essentially identical to our previous structures of the 
complete Pol II elongation complex (Kettenberger et al., 2004) and the elongation complex 
containing a CPD lesion at the polymerase active site (Brueckner et al., 2007). However, the 
downstream DNA duplex adopts a slightly altered position (Figure 2.3). The change in the 
downstream DNA position results from the presence of the cisplatin lesion rather than from 
the scaffold design or the nucleic acid sequences, which were highly similar to those used 
previously (Brueckner et al., 2007). Structures of free DNA containing a cisplatin lesion 
(Gelasco and Lippard, 1998; Takahara et al., 1995) reveal that the lesion at the center of the 
duplex leads to DNA bending. In our structure, the lesion is located at the end of the duplex 
and induces a slight repositioning of the downstream DNA, without substantial changes in its 
internal structure. 
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Table 2.1 Crystallographic data and refinement statistics for elongation complex A (scaffold A, 
cisplatin lesion at positions +2/+3).  
 Pol II EC with cisplatin lesion 
Data collection  
Space group C2221 
Cell dimensions  a, b, c (Å) 222.1, 393.1, 283.7 
Resolution (Å) 50.0-3.80 (4.02-3.80)1 
Rsym 8.8 (36.2) 
I / σI 11.2 (3.4) 
Completeness (%) 99.1 (97.0) 
Redundancy 3.4 (3.2) 
  
Refinement  
Resolution (Å) 50.0-3.80 
No. reflections 235,052 
Rwork / Rfree2 21.5 / 24.0 
No. atoms  
    Protein 31,102 
    Nucleic acids 698 
B-factors  
    Protein 115.5 
    Nucleic acids 144.0 
R.m.s. deviations  
    Bond lengths (Å) 0.008 
    Bond angles (°) 1.5 
Pt peak in anomalous  
difference Fourier (σ) 
23.5 
Diffraction data were collected from a single crystal. 1Values in parentheses are for the highest-
resolution shell. 2For free R-factor calculation, we excluded from refinement the same set of reflections 
that had been excluded from previous Pol II structure determinations (Armache et al., 2005; Brueckner 
et al., 2007; Kettenberger et al., 2004). 
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2.2.2 RNA polymerase II stalling and AMP misincorporation 
 
The crystal structure of complex A defines a state of the elongation complex in which the 
lesion lies downstream of the active site. We therefore used complex A in RNA-extension 
assays to investigate the mechanism of Pol II stalling. The RNA was labeled with a fluorescent 
dye at its 5’ end, complex A was incubated with NTP substrates, and the RNA-extension 
products were separated on polyacrylamide gels and visualized with a fluorimager (Figure 
2.4). After incubation with a physiological concentration of 1 mM NTPs for 20 min, most of the 
RNA was extended by two nucleotides (Figure 2.4a). Thus, the complex apparently stalled 
after nucleotide incorporation opposite the first guanosine (the 3’ guanosine) of the cisplatin 
lesion. Incubation of complex A with subsets of NTPs suggested that the terminal 
incorporation is a specific misincorporation of AMP (Figure 2.4a). To further investigate this, 
we prepared a scaffold that resulted in an elongation complex that was advanced by one 
position (scaffold B, Figure 2.2a). As expected, the results of incubation of complex B with 
individual NTPs again revealed AMP misincorporation (Figure 2.4a). 
A time course of RNA extension with complex A showed that the first incorporation 
event was fast, whereas the second incorporation - that is, the apparent misincorporation - 
was much slower and incomplete (Figure 2.4b, upper). Apparently, the initial incorporation is 
fast because GMP is correctly incorporated opposite a template cytidine and because the 
substrate site is free in complex A (Figure 2.2b), and translocation of the polymerase is not 
required. The slow rate of the second incorporation event was confirmed in a time course of 
RNA extension with complex B (Figure 2.4b, lower). This misincorporation event also required 
high ATP concentrations and was not observed in the presence of only 10 mM ATP (Figure 
2.4b). 
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Figure 2.4 Pol II stalling and lesion-directed misincorporation  
(a) RNA extension with scaffolds A and B. Lanes 1 and 7 show the fluorescently labeled reactant 
RNA. In the other lanes, the scaffolds were incubated with Pol II and different types of NTPs (1 
mM) for 20 min as indicated (Methods).  
(b) Time courses of the RNA extension reactions shown in A and dependence on the NTP 
concentration.  
(c) Possible base pair formation. Hydrogen bonds are indicated with dashed lines.  
(d) Adenine misincorporation does not result from template misalignment. Altered scaffolds 
were used, in which the thymine at the 5’ flanking position of the lesion was replaced by 
cytosine (Figure 2.5). The misincorporation seen in lane 2 is also observed with an undamaged 
scaffold (Figure 2.6) and is therefore not due to the lesion.  
(e) The 2-amino group at the 3’ position of the lesion is not involved in directing 
misincorporation. Altered scaffolds were used in RNA extension, in which the guanine at the 3’ 
position of the lesion was replaced by inosine.  
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Figure 2.5 Additional scaffolds used in RNA extension assays.  
The color code is indicated and used throughout. 
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Figure 2.6 Nucleotide incorporation using an undamaged scaffold.  
RNA extension assays with a scaffold that is identical to scaffold A but lacks the lesion. This 
experiment showed that A misincorporation occurs with this scaffold in the absence of a lesion 
at a position where templated incorporation leads to G incorporation. Incubation time was 5 
min, NTP concentration was 1 mM.  
 
2.2.3 Possible mechanisms for misincorporation 
 
As the template strand in our scaffold contained a thymidine immediately downstream of the 
cisplatin lesion, AMP misincorporation may have arisen from template misalignment, a 
recently characterized mechanism for misincorporation of nucleotides (Kashkina et al., 2006). 
During misalignment, the cisplatin lesion would transiently adopt a flipped-out, extrahelical 
conformation, and the thymidine flanking the lesion on the 5’ side would transiently occupy the 
position of the template base, at register +1 in the active site, to direct AMP incorporation. To 
test whether this was the case, we prepared a scaffold that was identical to scaffold A except 
that the flanking thymidine was replaced by cytidine (scaffold AT->C, Figure 2.5). This altered 
scaffold gave rise to the same RNA-extension products (Figure 2.4d), however, showing that 
template misalignment did not occur. We confirmed this by altering scaffold B and repeating 
the RNA-extension assay (Figure 2.4d). Another possible explanation for AMP 
misincorporation is that the 3’ guanosine of the lesion could act as a templating base by 
adopting a position that allows it to form two hydrogen bonds with the Watson-Crick positions 
of an incoming ATP substrate (Figure 2.4c). To test whether the third Watson-Crick position of 
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the 3’ guanosine in the lesion, the extracyclic 2-amino group, is involved in templating AMP 
misincorporation, we replaced the 3’ guanosine in the lesion with inosine, which lacks the 2-
amino group (Figure 2.4c). RNA-extension analysis showed that AMP was still specifically 
misincorporated when scaffolds A and B were modified by replacement of the GG cisplatin 
lesion with an IG cisplatin lesion (Figure 2.4e). Thus, AMP misincorporation does not involve 
the 2-amino group. These results were consistent with lesion-templated misincorporation 
involving a G-A base pair (Figure 2.4c), but we could not test this directly. 
 
2.2.4 Impaired entry of lesions into the active site 
 
If the AMP misincorporation is templated by the lesion, the lesion must adopt a position in the 
active site, at least transiently. However, structural considerations suggest that lesion entry 
into the active site would be impaired, because translocation of the cisplatin dinucleotide 
lesion from positions +2/+3 to positions +1/+2 is expected to be disfavored, as is the case for 
a dinucleotide photolesion (Brueckner et al., 2007). Template bases in positions +1/+2 are 
twisted against each other by about 90° in structures of the undamaged elongation complex 
(Gnatt et al., 2001; Kettenberger et al., 2004), but such twisting is impossible for nucleotides 
that are covalently linked in dinucleotide lesions, giving rise to a translocation barrier 
(Brueckner et al., 2007). To determine whether translocation of the cisplatin lesion is indeed 
impaired, we crystallized complex B, which was designed to contain the dimer at positions 
+1/+2 (scaffold B, Figure 2.2a). The anomalous difference Fourier map revealed a platinum 
peak at the same location where one was seen in complex A, indicating that the polymerase 
had apparently stepped backward by one position, so that the cisplatin lesion again occupied 
positions +2/+3 (Figure 2.7a). A lower height of the platinum peak (Table 2.2) indicated partial 
occupancy of the nucleic acids. Indeed, the electron density for the nucleic acids was weak 
and fragmented, and did not allow for model-building. Thus, the cisplatin lesion was not stably 
accommodated at positions +1/+2, and translocation from positions +2/+3 to positions +1/+2 
was apparently disfavored. These results suggest that the lesion does not stably bind the 
active site at all. To test this, we prepared a scaffold that contained the lesion at predicted 
positions –1/+1 in the active site, and a G-A mismatch pair at position –1 (scaffold C, Figure 
2.2a), and crystallized the resulting complex C. The anomalous difference Fourier map 
revealed a platinum peak at the same location as in complexes A and B, indicating that the 
polymerase had stepped backward by two positions so that the cisplatin lesion again occupied 
positions +2/+3 (Figure 2.7b). The height of the platinum peak was lower than for complexes 
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A and B (Table 2.2), and the electron density for the nucleic acids was again fragmented, 
preventing model-building. We also tried to solve a structure with the lesion placed at 
positions –2/–1 (scaffold D, Figure 2.2a). However, crystal structure analysis (Table 2.2) 
revealed no electron density for nucleic acids, consistent with a low affinity of this scaffold for 
the polymerase. Thus, the cisplatin lesion was not stably accommodated in the active site.  
 
Table 2.2: Additional crystallographic data statistics. 
Scaffold/complex1 B C D 
Designed position of cisplatin lesion +1/+2 -1/+1 -2/-1 
Data collection    
Space group C2221 C2 C2 
Unit cell axes (Å) 222.6, 394.1, 283.6 393.3, 222.3, 283.1  393.6, 222.4, 285.1  
Unit cell ß angle (°) 90 90.6 90.6 
Wavelength (Å) 1.07158 1.07155 1.07158 
Resolution range (Å) 50.0-4.0 (4.14-4.0)2 50.0-3.8 (3.94-3.8) 50.0-3.8 (3.94-3.8) 
Unique reflections 100,722 (9,484) 219,371 (22,754) 238,532 (24,245) 
Completeness (%) 98.7 (93.9) 98.1 (99.1) 99.8 (98.7) 
Rsym (%) 10.9 (38.8) 6.0 (27.2) 12.4 (35.5) 
I/σ(I) 21.4 (5.1) 12.0 (3.5) 9.0 (4.5) 
Pt peak in anomalous Fourier (σ) 18.2 12.5 - 
1Diffraction data were collected at the Swiss Light Source beamline PX1 and were processed with 
program XDS (Kabsch, 1993) or DENZO (Otwinowski, 1996) (complex B). 
2Numbers in parenthesis correspond to the highest resolution shells. 
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Figure 2.7 The cisplatin lesion is not stably accommodated in the active site.  
(a) Anomalous difference Fourier maps of the Pol II elongation complex B. The contour levels of 
the anomalous difference Fourier maps is 6σ. The model of complex A is shown. The view is 
from the side. 
(b) Anomalous difference Fourier map of the Pol II elongation complex C. The contour levels of 
the anomalous difference Fourier maps is 6σ. The model of complex A is shown. The view is 
from the side. 
 
2.2.5 Nontemplated AMP incorporation and an ‘A-rule’ for Pol II 
 
The crystallographic data strongly suggest impairment of translocation of the lesion to a 
position where it can direct AMP misincorporation. We therefore asked ourselves whether 
AMP incorporation resulted from nontemplated synthesis. Such preferential, nontemplated 
AMP incorporation occurs when DNA polymerases encounter a bulky DNA lesion and is 
known as A-rule (Strauss, 1991; Taylor, 2002). We prepared a scaffold identical to scaffold B, 
but containing an abasic site at the templating position +1 and containing no cisplatin lesion 
(scaffold Babasic, Figure 2.5). Indeed, AMP, and also to a lesser extent GMP, could be 
incorporated into RNA opposite the abasic position (Figure 2.8a), showing that Pol II 
Mechanism of transcriptional stalling at cisplatin-damaged DNA 28 
incorporates purine nucleotides, preferentially AMP, when a templating base is unavailable. 
The efficiency of nontemplated AMP incorporation was comparable to that of the terminal 
AMP misincorporation during stalling at a cisplatin lesion, as judged from the slow rate of the 
reaction and its dependence on NTP concentration (Figure 2.4b, Figure 2.8a). In the presence 
of the cleavage factor TFIIS, template GMP incorporation with scaffold A occurred normally, 
but nontemplated AMP incorporation was suppressed (Figure 2.8b), consistent with a role of 
TFIIS in transcriptional proofreading (Thomas et al., 1998; Wind and Reines, 2000). However, 
TFIIS was unable to promote passage over the translocation barrier. Together, these 
observations suggest that Pol II obeys an ‘A-rule’ for nontemplated nucleotide addition, which 
could explain the terminal AMP incorporation when the bulky cisplatin lesion is encountered. 
This mechanism is consistent with the model in which the cisplatin lesion does not enter the 
active site during elongation, not even transiently to direct terminal AMP incorporation. 
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Figure 2.8 RNA extension assays 
(a) Nontemplated purine incorporation at an abasic site. The scaffold used corresponds to 
scaffold B but contains an abasic site at the templating position +1 and no cisplatin lesion 
(Scaffold Babasic, Figure 2.5).  
(b) Effect of RNA cleavage factor TFIIS on RNA elongation with scaffold A. NTPs and TFIIS were 
either added simultaneously (lane 6), or sequentially as indicated by arrows with individual 
incubation times of 20 min (lanes 7-8). 
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2.2.6 Artificial bypass of a cisplatin lesion 
 
The above data suggest that impaired translocation and delivery of the lesion to the active site 
causes polymerase stalling, but do not exclude the possibility that stalling is due to the 
terminal AMP misincorporation and impaired elongation of the resulting G-A mismatch. To test 
whether polymerase stalling depends on the misincorporation event, we carried out RNA-
extension studies with scaffold C, which contained the misincorporated adenosine opposite 
the 3’ guanosine of the cisplatin lesion, and with a scaffold that contained the cognate cytidine 
at this position (scaffold E, Figure 2.2a). Incubation of complexes C and E with individual 
NTPs showed that CMP was correctly incorporated opposite the 5’ guanosine of the lesion, 
although AMP misincorporation also occurred, albeit less efficient (Figure 2.10a). The majority 
of elongation complexes C and E did not allow for RNA extension past the lesion (Figure 
2.10a), indicating that they are stably stalled and that stalling is independent of the G-A 
mismatch. Thus, misincorporation is not required for stalling. Prolonged incubation of scaffolds 
C and E with Pol II and NTPs, however, led to a small but reproducible amount of run-off 
products (Figure 2.10a). These products may be a result of lesion bypass. Alternatively, they 
may arise from deplatination of the DNA, maybe by transfer of the platinum to an amino acid 
side chain of Pol II. To investigate this, we analyzed the nucleic acid products resulting from 
prolonged incubation of complex A with Pol II and NTPs by MALDI mass spectrometry. Only 
intact, fully platinated template strand was observed (Figure 2.9), and this represents strong 
evidence against deplatination. Thus, the cisplatin lesion apparently can occupy the active site 
transiently if a nucleotide is present in the RNA opposite the 3’ guanosine of the lesion, 
enabling RNA extension past the lesion for a fraction of complexes. Modeling showed that 
entry of the bulky cisplatin lesion into the active site would require conformational changes but 
that the lesion, once entered, could be accommodated in the active site with only slight 
structural changes (Figure 2.10b). To provide further support for possible lesion bypass, we 
used scaffolds in which the RNA contained nucleotides opposite both guanosines of the 
cisplatin lesion (scaffolds D and F, Figure 2.2a). Incubation of the resulting elongation 
complexes with NTPs gave rise to efficient lesion bypass (Figure 2.10a). Notably, bypass was 
possible not only with a G-C match at the 3’ position of the lesion, but also with a G-A 
mismatch at this position (Figure 2.10a). These data show that lesion bypass is facilitated by 
RNA nucleotides that are already present in the scaffold opposite the lesion, most probably 
because this facilitates binding of the lesion beyond the translocation barrier, at positions –2/–
1, just upstream of the active site. Because Pol II can pass the lesion and a mismatch, stalling 
is not due to impaired extension of a lesion-containing hybrid or a mismatch. This supports the 
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model in which stalling results from impaired translocation and entry of the lesion into the 
active site. 
 
 
Figure 2.9 MALDI analysis of DNA platination.  
Complex A was incubated with NTPs overnight and the nucleic acids were subsequently 
subjected to MALDI mass spectrometry. The measured mass/charge ratio of the DNA template 
strand containing the cisplatin lesion (8016.1) compares well with the theoretical molecular 
weight of 8006 Da. There is no peak near the expected mass for a deplatinated strand (7777 Da). 
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Figure 2.10 Lesion bypass  
(a) RNA extension with scaffolds C, E, D, and F. Lanes 6, 12 and 18 show the fluorescently 
labeled reactant RNA. In the other lanes, the scaffolds were incubated with Pol II and different 
types of NTPs (1 mM) for 20 min as indicated (Methods). Run-off products are indicated (RO). 
Additional RNA extension assays confirmed these results (Figure 2.11).  
(b) Modeling of the cisplatin lesion at positions +1/-1. A cisplatin lesion was manually placed 
such that it superimposes with template nucleotides at the active center positions +1 and –1 of 
complex A. Due to some close contacts, in particular with threonine T831 in the bridge helix, 
minor conformational changes are required to accommodate the lesion. 
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Figure 2.11 Additional RNA extension assays.  
Additional RNA extension assays support the conclusions about cisplatin-induced Pol II 
stalling. The pattern of RNA products obtained after extension with scaffold C is different from 
the pattern obtained after pre-incubation of scaffold B with ATP, followed by all four NTPs. This 
difference can be explained by the translocation barrier. Scaffold B causes Pol II to backstep by 
one position (Figure 2.7a). This results in a location of the lesion before the translocation 
barrier. Preincubation with ATP results in nontemplated and inefficient A addition according to 
an A-rule, but there is no further extension since the translocation barrier cannot be overcome. 
In contrast, in scaffold C, there is an A residue already present at the 3’ end of the RNA. This 
results in a small population of complexes that accommodate the lesion at the active site 
(“lesion placed beyond the translocation barrier”) and which can be extended. As controls, very 
similar patterns of RNA products were observed for extension of scaffold D, and pre-incubation 
of scaffold C with CTP, followed by extension with all four NTPs, demonstrating the reliability of 
our assays. The run-off products deviate by a single nucleotide, as expected from the 
experimental design. Also, a very similar pattern of RNA products was obtained for extension of 
scaffold F, and pre-incubation of scaffold E with CTP, followed by extension with all four NTPs. 
Again, the run-off products deviate by a single nucleotide as expected. 
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2.3 Discussion 
 
In the structural and functional studies described here, we used cisplatin lesion–containing Pol 
II elongation complexes to investigate the detailed mechanism of transcriptional stalling at the 
most frequent cisplatin-induced DNA adduct. We show that Pol II stalls in front of a cisplatin 
lesion because it does not pass a translocation barrier that impairs delivery of the bulky lesion 
into the active site. When elongation complexes are prepared in which the lesion is positioned 
beyond the translocation barrier, bypass of the lesion is possible. To our surprise, stalled Pol II 
was able to incorporate AMP in an apparently nontemplated manner according to an A-rule 
that has been described previously for DNA polymerases (Strauss, 1991; Taylor, 2002). The 
A-rule may explain inefficient AMP incorporation not only at the cisplatin lesion, but also at the 
same position during transcription of another dinucleotide lesion, the TT CPD photolesion 
(Brueckner et al., 2007). This model supersedes the non-intuitive assumption that when CPD 
enters the active site, its 3’ thymidine acts as a template to direct AMP incorporation. AMP 
incorporation according to an A-rule enables formation of a matched T-A base pair at the 3’ 
position of the CPD, and this may stabilize the lesion in the active site (Brueckner et al., 
2007). In contrast, at the 3’ position of the cisplatin lesion, A-rule incorporation would result in 
a G-A mismatch if the lesion was able to cross the translocation barrier. Pol II bypassed the 
cisplatin lesion and the mismatch when they were artificially placed beyond the translocation 
barrier, showing that the barrier prevents efficient transcriptional mutagenesis and synthesis of 
substantial amounts of erroneous RNAs. Comparison of the results with the previously 
established mechanism of Pol II stalling at a CPD (Brueckner et al., 2007) reveals that Pol II 
stalls at the two dinucleotide lesions for different reasons (Figure 2.12). First, the cisplatin 
lesion cannot overcome the translocation barrier, but the CPD can, and the CPD binds in the 
active site. Second, inefficient AMP incorporation occurs at both lesions, but it enables lesion 
binding at the active site positions –1/+1 only for the CPD, probably because a stabilizing T-A 
base pair is formed at position –1, in contrast to a G-A mismatch that would be formed at the 
cisplatin lesion. Third, UMP misincorporation occurs opposite the 5’ nucleotide of the CPD, 
whereas correct incorporation occurs opposite the 5’ nucleotide of the cisplatin lesion, but only 
if the lesion is artificially placed beyond the translocation barrier. Fourth, AMP 
misincorporation at the cisplatin lesion is not required for stalling, but CPD-directed UMP 
misincorporation is required for stalling. Finally, the misincorporated nucleotide opposite the 
cisplatin lesion can be bypassed, whereas the misincorporated nucleotide opposite the CPD 
cannot. 
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Thus, the detailed mechanisms of transcriptional stalling at two different dinucleotide lesions 
differ in many respects. As a consequence, it is impossible to predict the mechanisms of 
transcriptional stalling or mutagenesis at other types of lesions. Instead, the detailed stalling 
mechanisms remain to be investigated for other lesions, including the less frequent 1,3-
d(GpNpG) intrastrand platinum cross-link (Jung and Lippard, 2006; Laine and Egly, 2006; 
Tornaletti et al., 2003; Tremeau-Bravard et al., 2004). Nevertheless, this study and our 
previous study of CPD-induced transcriptional stalling (Brueckner et al., 2007) suggest 
general aspects of the recognition of bulky dinucleotide lesions by Pol II, including a 
translocation barrier between positions +2/+3 and +1/+2, an A-rule for nontemplated 
nucleotide incorporation, and the possibility of lesion bypass under conditions that circumvent 
the natural stalling mechanism. 
Figure 2.12 Different mechanisms of Pol II stalling at dinucleotide lesions  
(a) Pol II stalling at the cisplatin lesion (this study) shown as a schematic representation of RNA 
extension in complex A. The initial RNA (top) corresponds to the non-extended RNA of scaffold 
A. The translocation barrier is indicated with a dashed horizontal line. The artificial situations 
leading to lesion bypass are depicted at the bottom.  
(b) Pol II stalling at a CPD lesion, adapted from (Brueckner et al., 2007). 
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3 Molecular basis of transcriptional mutagenesis at 8-oxoguanine 
 
3.1 Introduction 
 
Reactive oxygen species are generated in cells by aerobic respiration, and by exposure to 
ionizing radiation, transition metals, chemical oxidants or free radicals. Reactive oxygen 
species can damage DNA, in particular by converting guanine to 8-oxoguanine (8oxoG). 
8oxoG is the major mutagenic lesion in the genome (Lindahl, 1993) and can form a Watson-
Crick base pair with cytosine, but also a Hoogsteen base pair with adenine, since oxidation at 
the C8-position converts the N7 hydrogen bond acceptor to a hydrogen bond donor (Figure 
3.1a)(Hsu et al., 2004). Previous studies revealed that mammalian Pol II incorporates cytosine 
or adenine opposite 8oxoG, and can bypass the lesion (Kathe et al., 2004; Kuraoka et al., 
2003; Tornaletti et al., 2004). Lesion bypass is enhanced by TFIIS, which stimulates Pol II 
backtracking and 3’ RNA cleavage, although this enhancement apparently does not lead to a 
substantial removal of misincorporated adenine (Charlet-Berguerand et al., 2006; Kuraoka et 
al., 2007). The molecular mechanism of 8oxoG processing by RNA polymerases however 
remained to be elucidated.  
Here we combined functional assays and X-ray crystallography to derive the detailed 
molecular mechanism of transcription by Pol II from the yeast S. cerevisiae over DNA that 
contains an 8oxoG lesion in the template strand. We show that Pol II can misincorporate 
adenine at 8oxoG, and that the misincorporated adenine escapes intrinsic polymerase 
proofreading and remains in the transcript upon elongation, resulting in transcriptional 
mutagenesis. The mutant transcript is observed directly by mass spectrometry. We then use 
X-ray analysis to show that the misincorporated adenine forms a Hoogsteen base pair with 
8oxoG at the Pol II active center. In contrast, 8oxoG forms a standard Watson-Crick base pair 
with a correctly incorporated cytosine. Finally, we suggest a mechanism for mutagenic 
transcription and its suppression by TFIIS. 
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3.2 Results 
 
3.2.1 Yeast Pol II slowly misincorporates adenine at 8oxoG.  
 
To elucidate recognition and processing of 8oxoG-induced DNA damage by transcribing Pol 
II, we carried out a structure-function analysis of reconstituted Pol II elongation complexes 
(ECs) containing an 8oxoG lesion at defined positions in the DNA template strand. ECs were 
reconstituted from pure, complete 12-subunit Saccharomyces cerevisiae Pol II and minimal 
nucleic acid scaffolds as described (Damsma et al., 2007). An 8oxoG lesion was included at 
position +1 of the template strand (Figure 3.1b, scaffold A). In the resulting EC (complex A), 
the lesion lies in the polymerase active site, directly opposite the site that binds the nucleoside 
triphosphate (NTP) substrate, the nucleotide addition site (Figure 3.1b, scaffold A). To monitor 
RNA extension, we added a fluorescent label to the RNA 5’ end. EC A was incubated with 
NTP substrates, and the RNA products were separated on a polyacrylamide gel and 
visualized with a fluorimager (Figure 3.1c). Incubation with a physiological concentration of 1 
mM NTPs led to RNA extension and accumulation of the run-off product (Figure 3.1c, lanes 1-
3). Very similar results were obtained in RNA extension assays with an undamaged template 
(Figure 3.2), showing that 8oxoG does not strongly interfere with Pol II elongation, consistent 
with published data (Kathe et al., 2004; Tornaletti et al., 2004). Lesion bypass was possible 
with scaffolds that contained 8oxoG opposite register +1, but also with scaffolds that 
contained the lesion within the upstream DNA, at register +3 (not shown). 
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Figure 3.1. 8oxoG can direct slow adenine misincorporation.  
(a) Base pairing properties of 8-oxoG. 8oxoG differs from guanine by an additional oxygen atom 
connected to C8, which results in an NH group at N7.  
(b) Nucleic acid scaffolds. The indicated color code is used throughout. The RNA was 5’ end-
labeled with 6-carboxyfluoresceine (FAM) and an UGCAU linker. Filled circles denote 
nucleotides present in the structures (Figure 3.5).  
(c) RNA extension with EC A.  
(d) Time courses of incorporation with CTP or misincorporation with ATP. The indicated 
complementary scaffold was used. The DNA nontemplate was 5’ end-labeled with Biotin with the 
use of a TTTTT linker. The RNA was 5’ end-labeled with 6-carboxyfluoresceine (FAM) and an 
UGCAU linker. 
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Incubation with individual NTPs showed that both cytosine and adenine are 
incorporated opposite the lesion (Figure 3.1c, lanes 4-11). Uridine was also incorporated, but 
this was also observed for undamaged DNA (Figure 3.2), and is caused by a lesion-
independent mechanism called template misalignment (Kashkina et al., 2006). Incubation with  
GTP also resulted in some misincorporation (Figure 3.1c, lanes 4-11) and for undamaged 
DNA some misincorporation of ATP was also observed (Figure 3.2), but these 
misincorporations are at a level expected from yeast Pol II in the absence of TFIIS (Sydow et 
al., 2009). To further investigate adenine misincorporation and cytosine incorporation opposite 
the lesion, we performed a time course analysis with an EC that contained a fully 
complementary complete scaffold, which results in a natural, complete EC coupled to 
magnetic beads (Dengl and Cramer, 2009). This revealed that adenine misincorporation was 
about 34-fold slower than cytosine incorporation (Figure 3.1d), suggesting a misincorporation 
frequency of a few percent, consistent with data for mammalian Pol II (Charlet-Berguerand et 
al., 2006). Thus misincorporation events are rare but occur at a significant frequency. 
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Figure 3.2 RNA extension assays.  
The lanes show the fluorescently labeled RNA. The scaffolds were incubated with Pol II and 
indicated NTPs for the time that is indicated above. On the left, 1 mM NTP mix was used to 
elongate scaffold A with an 8-oxoguanine or with a normal guanine (Scaffold Aundamaged). On the 
right, single NTPs were added to undamaged scaffold A, different concentrations where used, 
as indicated. 
 
3.2.2 Adenine misincorporation results in transcriptional mutagenesis.  
 
The above results suggest that both adenine and cytosine can be incorporated opposite 
8oxoG, but could not clarify whether adenine misincorporation also occurs in the presence of 
the correct CTP substrate. To test this, we performed RNA extension assays in the presence 
of both CTP and ATP. We established a protocol to analyze the RNA products, which 
contained the additionally incorporated nucleotide, by MALDI mass spectrometry. The method 
allowed us to distinguish between the RNA product that included the correctly incorporated 
cytosine and the product that included the misincorporated adenine, although the expected 
mass difference was only 24 Da (Figure 3.3a). 
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 When the ratio of ATP to CTP was 1:1, mass spectrometry was unable to 
unambiguously detect adenine misincorporation, since the mass of the misincorporation 
product is indistinguishable from the mass of the cytosine incorporation product associated 
with a sodium ion that has a mass of 23 Da (Figure 3.3a). However, when the ratio of ATP 
over CTP was increased, product RNA that contained the misincorporated adenine was 
readily detected (Figure 3.3a). When a 1000-fold excess of ATP over CTP was used, 
essentially all incorporation events were misincorporations. Thus, in the presence of both CTP 
and ATP, both cytosine and adenine can be incorporated opposite 8oxoG, although the 
correct cytosine incorporation is more frequent, consistent with the faster rates observed 
above. These competition assays and the kinetic data show that 8oxoG triggers adenine 
misincorporation even in the presence of the correct substrate, and suggest that the frequency 
of misincorporation is in the range of a few percent. 
 
3.2.3 8oxoG-triggered misincorporation results in transcriptional mutagenesis 
 
The above data show that both cytosine and adenine are incorporated by Pol II opposite 
8oxoG, but do not exclude that before further elongation the misincorporated adenine is 
removed by the intrinsic proofreading function of the polymerase. We therefore investigated 
whether a misincorporated adenine is maintained in the RNA upon elongation. Complex A 
was incubated with all four NTPs, and the resulting run-off product was analysed by MALDI 
mass spectrometry. This revealed the expected mass for the correct RNA run-off product, but 
again was unable to unambiguously detect adenine misincorporation, since the mass of the 
misincorporation product was indistinguishable from the mass of the cytosine incorporation 
product associated with a sodium ion (Figure 3.3b). To facilitate the analysis, we aimed to 
increase the level of adenine misincorporation opposite 8oxoG. Complex A was pre-incubated 
with ATP, followed by addition of the other three NTPs. Subsequent MALDI analysis showed 
that the run-off product contained the misincorporated adenine (Figure 3.3b). These data 
show that 8oxoG can cause adenine misincorporation in the presence of CTP, and the 
inserted adenine escapes polymerase-intrinsic proofreading and remains in the RNA, leading 
to transcriptional mutagenesis. 
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Figure 3.3 Adenine misincorporation can lead to transcriptional mutagenesis.  
(a) Complex A was incubated for 5 minutes with mixtures of ATP (1 mM) and CTP at different 
ratios as indicated. The nucleic acids were desalted and subjected to MALDI mass 
spectrometry. The observed mass/charge curves are given. The expected mass of the RNA 
strand was 5900 Da if a cytosine was incorporated and 5924 Da if an adenine was incorporated. 
Decreasing the amount of competing CTP in the reaction mixture increased the extent of 
adenine misincorporation.  
(b) Misincorporated adenine can remain in a run-off RNA product. On the left, RNA extension 
assays with complex A are shown. Complex A was incubated with all four NTPs (1 mM) for 60 
min or preincubated with ATP for 5 minutes, and then incubated with all four NTPs for 60 min. 
The run-off product is indicated (RO). The nucleic acids were desalted and subjected to MALDI 
mass spectrometry. On the right, mass spectrometric detection of the run-off RNA is shown. 
The calculated mass of the run-off product was 10393 Da if a cytosine was incorporated 
opposite 8oxoG and 10417 Da if an adenine was misincorporated opposite 8oxoG. 
Preincubation with ATP increases the amount of mutated RNA run-off product and thus enables 
direct observation of the mutated RNA. 
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3.2.4 TFIIS removes a misincorporated adenine.  
 
The above results show that an 8oxoG-adenine mismatch base pair, once formed in the 
polymerase active site, escapes the intrinsic proofreading function of Pol II. However, since 
the RNA cleavage-stimulatory factor TFIIS can enhance Pol II proofreading (Jeon and 
Agarwal, 1996; Thomas et al., 1998), we investigated whether TFIIS can stimulate removal of 
a misincorporated adenine opposite the 8oxoG lesion. For RNA extension assays in the 
presence of TFIIS we first used scaffolds B and C, which already contained cytosine or 
adenine, respectively, at the RNA 3’ end opposite the 8oxoG lesion (Figure 3.1b). We added 
recombinant TFIIS to the obtained ECs B and C, and incubated the mixture for 5 minutes. 
This led to cleavage of a RNA 3’ dinucleotide, which was not observed for undamaged DNA 
containing a G-C match (scaffold Bundamaged, Figure 3.4). Dinucleotide cleavage generally 
occurs in the presence of TFIIS (Izban and Luse, 1993), and was also observed for 
undamaged DNA containing a G-A mismatch (scaffold Cundamaged, Figure 3.4). Upon 
subsequent incubation with NTPs for 5 minutes, RNA was elongated (Figure 3.4). MALDI 
analysis of run-off RNA produced by EC C, incubated with both TFIIS and NTPs for 5 minutes, 
indicated replacement of the RNA 3’ adenine by cytosine (data not shown). This showed that 
TFIIS had stimulated removal of the misincorporated adenine from the RNA prior to 
elongation. These data suggest that TFIIS suppresses transcriptional mutagenesis by 
stimulating proofreading, but do not demonstrate proofreading under rapid elongation 
conditions. During rapid elongation, proofreading apparently does not occur to a large extent, 
at least with mammalian Pol II (Charlet-Berguerand et al., 2006). 
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Figure 3.4 Effect of cleavage factor TFIIS on RNA elongation with ECs B and C.  
Lanes 4 and 12 show the control experiments where fluorescently labelled RNA was incubated 
with Pol II and no RNA extension had taken place. In lanes 2 and 10, TFIIS was added for 5 min 
to undamaged complexes Bundamaged and Cundamaged, respectively, which contained guanine 
instead of 8oxoG. In lanes 3 and 11, TFIIS was added for 5 min to complexes B and C, 
respectively. As expected, cleavage products were observed in lanes 2, 3, 10, and 11 (a product 
that arises from TFIIS-induced backtracking and cleavage is indicated by #). In other lanes, the 
scaffolds were incubated with Pol II, NTPs (1 mM) and/or TFIIS for 5 min as indicated. Run-off 
products are indicated (RO). NTPs and TFIIS were added either simultaneously (lanes 6 and 14) 
or sequentially as indicated by arrows, with individual incubation times of 5 min (lanes 7, 8, 15, 
and 16). The stars on the right indicate RNA impurities that were already present in the starting 
RNA material. The “#” indicates a cleavage product after backtracking. 
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3.2.5 8oxoG and the misincorporated adenine form a Hoogsteen pair.  
 
To investigate the molecular basis for 8oxoG transcription, we solved crystal structures of Pol 
II ECs containing 8oxoG (Methods). When we included 8oxoG at position -1 of the DNA 
template strand (Figure 3.1b, scaffold C), the obtained electron density for the nucleic acids 
was not interpretable, indicating a mixture of pre- and post-translocation states (Brueckner 
and Cramer, 2008). An interpretable electron density map was however obtained when we 
included an 8oxoG-C DNA-RNA base pair at the penultimate position in the hybrid (Figure 
3.1b, scaffold D). The structure was solved at 3.7 Å resolution (Table 3.1, Figure 3.5). A 
bromine atom that had been included in the template strand as a marker gave rise to a single 
peak in an anomalous difference Fourier map and unambiguously defined the nucleic acid 
register. The EC was not post-translocated but adopted a state with a frayed RNA 3’ end at 
register +1. This RNA fraying does not influence our analysis as it occurred also in a control 
structure with undamaged DNA (Figure 3.6). We recently published a detailed structural 
analysis of RNA fraying and showed that it occurs with different types of terminal RNA 
nucleotides and that frayed nucleotides can be stabilized by a neighboring mismatch pair 
(Sydow et al., 2009). The overall structure was generally similar to that of the undamaged 
complete Pol II EC (Kettenberger et al., 2004) (Figure 3.5a, b). The 8oxoG-C base pair 
adopted standard Watson-Crick geometry at register -1, consistent with normal cytosine 
incorporation opposite guanine (Figure 3.5c). An additional structure was solved at 3.9 Å 
resolution with the 8oxoG as above, but containing an adenine, instead of cytosine, in the 
RNA opposite the lesion (Figure 3.1b, Figure 3.5, scaffold E,Table 3.1). The unbiased 
difference electron density map for the nucleic acids showed a distinct density for the nascent 
base pair that did not adopt Watson-Crick geometry. When the 8oxoG residue was placed in 
the standard anti conformation it did not fit the density. However, when it was rotated by 180 
degrees and placed in a syn conformation, it fitted the density very well and was in a good 
position to form a Hoogsteen base pair with the adenine in the opposite RNA strand (Figure 
3.5c). Taken together, the structural analyses showed that 8oxoG can form a Watson-Crick 
base pair with a correctly incorporated cytosine, but can also form a Hoogsteen base pair with 
a misincorporated adenine (Figure 3.5c). 
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Figure 3.5 Structures of 8oxoG-containing Pol II ECs 
(a) Overview of the structure of the 8oxoG-containing Pol II EC D. Pol II is shown as a ribbon 
model in silver, with the bridge helix highlighted in green. The nucleic acids are in colour, and 
8oxoG is shown as a stick model in orange. A large portion of Pol II was omitted for clarity.  
(b) Structure of nucleic acids in the Pol II EC E. The final 2Fo-Fc electron density map is shown 
for the nucleic acids (blue, contoured at 1.0σ). The anomalous difference Fourier map reveals 
the location of the bromine atom as indicated (red, contoured at 3.5σ). 
(c) 8oxoG-containing base pairs observed in EC structures. On the top, the Watson-Crick 
8oxoG-C base pair observed in EC D is shown. On the bottom, the 8oxoG-A Hoogsteen base 
pair observed in EC E is depicted. The unbiased Fo-Fc difference electron density map is shown 
as a green mesh contoured at 2.7σ. Hydrogen bonds are indicated with dashed lines. 
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Figure 3.6 Control structure of an undamaged Pol II elongation complex.  
The density map of undamaged Pol II elongation complex D (scaffold Dundamaged). The difference 
FO-FC density map of the nucleic acids is shown (green, contoured at 3.0σ). The model of 
complex D is shown. The frayed RNA which was found in the structure of complex D, can also 
be seen for the undamaged structure. 
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Table 3.1 Crystallographic data and refinement statistics for complete Pol II elongation 
complexes (ECs) 
Data collection EC D EC E 
Space group C2221 C2221 
Unit cell axes (Å) 220.6, 392.0, 281.5 221.2, 394.1, 282.3 
Wavelength (Å) 0.9188 0.9186 
Resolution range (Å) 50.0-3.7 (3.8-3.7)
2 50.0-3.9 (4.0-3.9)2 
Unique reflections 250,702 (19,429) 216,612 (15,791) 
Completeness (%) 99.6 (99.9) 99.7 (99.8) 
Rsym (%) 8.2 (56.7) 7.8 (86.3) 
I/σ(I) 11.9 (2.7) 13.4 (2.6) 
Redundancy 3.8 (3.8) 3.9 (4.0) 
Refinement   
Nonhydrogen atoms 32,348 32,298 
RMSD bonds (Å) 0.008 0.008 
RMSD angles (°) 1.50 1.48 
Peak in anomalous difference Fourier (σ) 6.7 5.1 
Rcryst (%) 22.5 22.8 
Rfree (%) 25.8 26.6 
1Diffraction data were collected at the Swiss Light Source beamline PX1 (X06SA) and were 
processed with program XDS (Kabsch, 1993). 
2Numbers in parenthesis correspond to the highest resolution shells. 
 
3.3 Discussion 
 
Here we presented structural and functional studies of 8oxoG-containing Pol II ECs to 
investigate the detailed mechanism of 8oxoG lesion processing during gene transcription. We 
have shown that yeast Pol II can misincorporate adenine at an 8oxoG lesion in the DNA 
template strand, that the misincorporated adenine forms a Hoogsteen base pair with the 
lesion at the polymerase active center, and that the misincorporated adenine escapes 
polymerase-intrinsic proofreading and remains in the RNA as a product of transcriptional 
mutagenesis. 
How may misincorporation and proofreading occur? In incoming DNA, 8oxoG likely 
adopts a standard anti conformation within a Watson-Crick base pair, but its base must rotate 
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by 180º to the syn conformation in the 8oxoG-A DNA-RNA Hoogsteen base pair at the active 
center. Modelling shows that base rotation in the templating position at register +1 would 
result in a clash with the bridge helix and the DNA base at register -1. We therefore propose 
that base rotation occurs during 8oxoG translocation from the downstream position +2 to the 
templating position +1 in the recently described state of the EC that was suggested to be an 
intermediate of translocation (Brueckner and Cramer, 2008). DNA translocation from +2 to +1 
apparently passes through an intermediate state, which contains the unpaired template base 
in a pre-templating position (Brueckner and Cramer, 2008). In this position the 8oxoG base 
would be unpaired and free to rotate from anti to syn before being loaded into the templating 
position. The loaded 8oxoG in syn conformation then triggers adenine misincorporation by 
Hoogsteen base pair formation with an incoming ATP substrate. The resulting 8oxoG-A base 
pair mimics a T-A base pair and is accommodated in the polymerase active center and in the 
DNA-RNA hybrid, leading to an escape from intrinsic proofreading and enabling synthesis of a 
mutated RNA and thus transcriptional mutagenesis. TFIIS induces backtracking of 8oxoG 
from the active center to downstream DNA. When repeated translocation preserves the anti 
conformation, correct cytosine incorporation occurs, and RNA is elongated error-free. 
 Transcriptional mutagenesis as demonstrated here in vitro may be a threat in vivo, 
published results indicate that the molecular mechanism of transcriptional mutagenesis 
described here is relevant in vivo. In particular, it was reported that a yeast strain lacking dst1, 
the gene encoding TFIIS, is sensitive to oxidative stress (Koyama et al., 2003; Koyama et al., 
2007). Our study suggests that this sensitivity stems from the accumulation of mutant RNA 
transcripts, which result from the failure of the intrinsic Pol II proofreading activity to remove 
adenine that was misincorporated opposite 8oxoG. An additional contribution to the sensitivity 
to oxidative stress may come from conversion of GTP to 8oxoGTP and subsequent 
incorporation of 8oxoG into RNA opposite a templating adenine (Koyama et al., 2003). In E. 
coli, 8oxoG-triggered transcriptional mutagenesis also occurs in vivo (Bregeon et al., 2003). 
Comparison of our results with previously published biochemical studies of 8oxoG 
processing reveals that the ratio of 8oxoG-dependent incorporation of adenine over cytosine 
differs for different RNA polymerases. We showed here that S. cerevisiae Pol II mainly 
incorporates cytosine opposite 8oxoG but can also misincorporate adenine to a low extent. 
Cytosine and adenine are however incorporated at similar levels by mammalian Pol II 
(Kuraoka et al., 2003; Yamaguchi et al., 2007) and by E. coli RNA polymerase (Viswanathan 
and Doetsch, 1998), whereas the RNA polymerase of bacteriophage T7 even prefers to 
incorporate adenine opposite 8oxoG (Chen and Bogenhagen, 1993). 
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The investigation of three different DNA template lesions with Pol II allows us to 
compare their effect on transcription and the mechanisms involved in each case. A UV-
induced thymine-thymine cyclobutane pyrimidine dimer (CPD) lesion can enter the 
polymerase active site and trigger uridine misincorporation, which leads to transcriptional 
stalling (Brueckner et al., 2007). In contrast, a cisplatin-induced 1,2-guanine-guanine crosslink 
lesion stalls Pol II because it cannot be translocated from the downstream DNA into the active 
site, resulting in nontemplated adenine misincorporation (Damsma et al., 2007). Thus, 
misincorporation occurs at all three lesions studied thus far, but for different reasons and with 
different consequences. At a CPD, misincorporation is required for stalling (Brueckner et al., 
2007). At the cisplatin crosslink, the lesion alone can stall Pol II, and misincorporation is a 
result of stalling (Damsma et al., 2007). At 8oxoG, misincorporation occurs in addition to 
correct incorporation, but does not stall the polymerase and rather leads to transcriptional 
mutagenesis when TFIIS is unavailable. Thus, as predicted (Brueckner et al., 2007; Damsma 
et al., 2007), the mechanisms of lesion processing differ for all lesions analyzed in 
mechanistic detail thus far. 
 Like RNA polymerases (Chen and Bogenhagen, 1993; Kuraoka et al., 2007; 
Viswanathan and Doetsch, 1998; Yamaguchi et al., 2007), DNA polymerases can incorporate 
cytosine or adenine opposite 8oxoG to various extents (Broyde et al., 2008; Hsu et al., 2004; 
Maga et al., 2007; Rechkoblit et al., 2006). High-fidelity DNA polymerases accommodate and 
bypass an 8oxoG-C base pair (Brieba et al., 2004; Freisinger et al., 2004; Hsu et al., 2004; 
Krahn et al., 2003). One structure of a high-fidelity DNA polymerase revealed an 8oxoG-A 
Hoogsteen base pair (Hsu et al., 2004). This suggests that the same mechanism of adenine 
misincorporation at 8oxoG occurs during replication and transcription, and that stable 
Hoogsteen pairing can occur within nucleic acid polymerases even though the active centers 
are structurally complementary to very different B- and A-form template-product duplexes in 
these structurally unrelated DNA and RNA polymerases, respectively. 
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4 Structure of the archaeal Spt4/5 core complex 
 
4.1 Introduction 
 
In all living organisms, transcription of protein-encoding genes is mediated by a common 
multiprotein machinery (Allison et al., 1985). There are numerous factors that regulate 
transcription by influencing the ability of RNA polymerase to access, bind, and transcribe 
specific genes in response to appropriate signals. Prokaryotic N-utilization substance G 
(NusG) is a well-conserved regulator of gene expression, which has a complex role in 
transcription elongation. NusG accelerates the elongation rate of E. coli RNA polymerase by 
suppression of specific polymerase pause sites (Burova et al., 1995). NusG was also found to 
facilitate Rho-dependent transcription termination by bridging Rho to RNA polymerase 
(Nehrke and Platt, 1994; Sullivan and Gottesman, 1992). Furthermore, NusG is involved in 
anti-termination of transcription, which is induced by the N protein of bacteriophage λ (Li et al., 
1992). NusG proteins have an N-terminal NusG (NGN) domain and a C-terminal KOW 
(Kyprides, Ouzounis, Woese) domain, a nucleic-acid binding domain also found in some 
ribosomal proteins (Ponting, 2002; Steiner et al., 2002). 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 4.1 Overview of the eukaryotic Spt4, Spt5 and the prokaryotic NusG, RpoE”. 
Conserved motifs are shown as boxes. The C-terminal part of Spt4 is absent in RpoE”. Residue 
numbers refer to S. cerevisiae Spt5. Adopted from (Guo et al., 2008). 
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The eukaryotic ortholog of NusG is Spt5. Spt5 has an acidic N-terminus, a single NGN 
domain, five or six KOW domains and a C-terminal sequence with a set of simple repeats that 
are targets of regulatory kinases (Figure 4.1)(Ponting, 2002; Saunders et al., 2006). Spt4 and 
Spt5 together, form the stable heterodimer “DRB Sensitivity Inducing Factor” (DSIF) (Wada et 
al., 1998), which interacts with Pol II (Hartzog et al., 1998; Yamaguchi et al., 1999b) and is 
involved in inhibiting or activating transcription elongation depending on the existence of 
Negative Elongation Factor (NELF) (Cheng and Price, 2007; Yamaguchi et al., 1999a). It was 
also shown that DSIF is involved in rRNA transcription, since mutations in DSIF caused 
defects of Pol I function (Schneider et al., 2006). Another function of Spt5 is to suppress 
senescence and apoptosis, which is exerted through the Spt5 association with Spt4 and Pol II 
(Komori et al., 2009). 
 Recently, the structure of an archaeal Spt5NGN domain (Methanocaldococcus 
jannaschii Spt5NGN) was published (Zhou et al., 2009). Also the yeast structure of the Spt4/5 
heterodimer was published as a fusion protein (Guo et al., 2008). To further investigate the 
Spt4/5 core complex from the archaea M. jannaschii we elucidated the structure of the first 
genuine Spt4/5 core complex at 1.9 Å resolution. 
 
4.2 Results & Discussion 
 
4.2.1 Solving the structure of the archaeal Spt4/5 core complex 
 
In collaboration with Dr. Finn Werner (University College London), crystals were obtained from 
the core Spt4/5 complex from the archaea Methanocaldococcus jannaschii (Methods) and 
exposed to synchrotron radiation (X06SA, SLS). All the crystals obtained were very thin 
plates, resulting in poorly defined diffraction spots when exposed through the shortest axis of 
the plate, and often resulted in datasets that were less than 100% complete. Subsequently, 
the anomalous signal from the predicted protein-bound zinc atom was too low for 
experimental phasing. Therefore, several attempts were made to solve the structure of the 
archaeal Spt4/5 core complex using molecular replacement with the S. cerevisiae structure as 
a search model (Guo et al., 2008). Although these attempts initially failed, publication of the 
structure of the core Spt5 from Methanocaldococcus jannaschii (Zhou et al., 2009) provided a 
better search model and made molecular replacement possible (Methods). The structure was 
build and refined using the programs Coot (Emsley and Cowtan, 2004), Refmac (Vagin et al., 
2004) and phenix.refine (Afonine et al., 2005). The final resolution was 1.9 Å (Table 4.1).  
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Table 4.1: Crystallographic data and refinement statistics for core Spt4/5 
Data collection  
Space group P21 
Unit cell axes (Å) 64.4 64.0 83.0  
90.0 107.0  90.0 
Wavelength (Å) 1.000 
Resolution range (Å) 44.4 – 1.9 (2.0 – 1.9) 
Unique reflections 47,050 
Completeness (%) 92.1% (86.4%) 
Rsym (%) 4.6 (59.6) 
I/σ(I) 9.65 (1.40) 
Redundancy 1.9 
Refinement  
Nonhydrogen atoms 4745  
RMSD bonds (Å) 0.008 
RMSD angles (°) 1.039 
Rcryst (%) 20.8 
Rfree (%) 25.5 
1Diffraction data were collected at the Swiss Light Source beamline PX1 (X06SA) and were 
processed with program XDS (Kabsch, 1993). 
2Numbers in parenthesis correspond to the highest resolution shells. 
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4.2.2 Details concerning the structure of the archaeal Spt4/5 core complex 
 
The Spt5NGN domain consists of a four-stranded antiparallel beta sheet flanked by three 
alpha helices (Figure 4.2). Spt4 has four beta strands in its center, with an alpha helix at the 
edge of the sheet. Spt4 contains a zinc finger, formed by four conserved cysteine residues 
and is located at the opposite side of the beta sheet. Zinc binding was confirmed by the X-ray 
absorption edge scan of Spt4/Spt5NGN crystals (Figure 4.3). Mutations altering any of the 
four finger cysteines of S. cerevisiae Spt4 cause loss-of-function phenotypes and in several 
instances greatly decrease Spt4 levels (Basrai et al., 1996; Malone et al., 1993). Thus, it is 
likely that the zinc finger is an essential structural element of Spt4 (Guo et al., 2008). 
 
 
Structure of the archaeal Spt4/5 core complex 55 
     
 
Figure 4.2 Structure of the Spt4/5 core complex from M. jannaschii.  
(a) The structure is shown as a cartoon representation, with Spt4 in wheat, Spt5 in red, and the 
zinc atom is shown as a blue sphere. 
(b) Close-up of the Spt4-Spt5NGN interface. The view is as in the right part of (A). 
 
  
  
90° 
A 
B 
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Figure 4.3 X-ray absorption edge scan of Spt4/5NGN crystals. 
The peak around 9670 eV corresponds to the K absorption edge of Zn (theoretical value 9659 
eV). 
 
The Spt4-Spt5 heterodimer consists of an 8-stranded antiparallel β sheet formed by 
the four stranded β sheet of Spt4 and the four stranded β sheet of Spt5, aligned edge to edge 
(Figure 4.2). In addition to this β sheet interface, several hydrogen bonds contribute to the 
specificity of Spt4-Spt5NGN interactions. In particular, Ser39 from Spt4 forms a conserved 
hydrogen-bonding interaction with Glu46 in Spt5NGN (Figure 4.2b). This hydrogen bond fixes 
Glu46, which results in a strong acid-α-helix dipole interaction (Guo et al., 2008; Nicholson et 
al., 1988). Thus, Spt4 and Spt5NGN interact via hydrophobic interfaces that are held in 
register by polar interactions and alignment of their β sheets. 
 
4.2.3 Structural conservation of Spt4 and Spt5NGN domain 
 
Comparison of the sequence and structure of the archaeal Spt5NGN domain with 
those of bacterial NusG and of eukaryotic Spt5NGN reveals conservations between bacteria, 
archaea and eukaryotes (Figure 4.4). Comparison of the structure of Spt5NGN of M. 
jannaschii, E. coli and S. cerevisiae also showed this conservation (Figure 4.5). The Spt5 
protein is found in all three kingdoms of life and is therefore one of the most ancient 
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components of the transcriptional machinery (Ciampi, 2006; Guo et al., 2008; Harris et al., 
2003; Ponting, 2002). The structural similarities of the NGN domain in archaea, bacteria and 
eukaryotes imply that they also share similar mechanisms of transcription regulation. 
Comparison of the sequence of archaeal Spt4 and eukaryotic Spt4 reveals 
conservation between archaea and eukaryotes. In contrast to Spt5, there are no Spt4 
sequence homologs in bacteria. Comparison of the structure of Spt4 of M. jannaschii and S. 
cerevisiae also showed conservation, for example the zinc finger is highly conserved (Figure 
4.6). The S. cerevisiae Spt4 is also larger; the extra residues form helices and lie adjacent to 
the zinc finger, which is located on the opposite edge of the sheet that forms the 
Spt4/Spt5NGN binding interface, hence maintaining the interface in both structures. The lack 
of these helices in M. jannaschii Spt4 exposes the zinc finger although, whether the zinc finger 
has a nucleic-acid binding ability in the transcription elongation complex needs to be studied 
further. When comparing the sequence of Spt4 and Spt5NGN the binding interface is 
conserved between eukaryotes and archaea (shaded area in Figure 4.4). For bacteria 
however there is no corresponding binding partner, although the bacterial Spt5NGN does 
have an appendant domain, which folds into a hairpin at the position close to where Spt4 
locates (Figure 4.5). This appendant domain was suggested to work as a structural element, 
such as a post or a stack, rather than as a site for residue-specific contacts in E. coli Spt5 
(Richardson and Richardson, 2005; Zhou et al., 2009). Whether Spt4 and the appendant 
domain have a similar function remains to be investigated. 
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Figure 4.5 Structural superimposition of the Spt5NGN domain. 
The M. jannaschii Spt5NGN domain is shown in firebrick. The E.coli NusG (pdb-code 2OUG) is 
shown in blue, and the S. cerevisiae Spt5NGN domain (pdb-code 2EXU) is shown in green. 
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Figure 4.6 Structural superimposition of Spt4. 
The M. jannaschii Spt4 is shown in wheat. The S. cerevisiae Spt4 (pdb-code 2EXU) is shown in 
green. 
 
4.2.4 Surface analysis of the hydrophobic patch 
 
The Spt5NGN domain was suggested to bind the largest subunit of RNA polymerase II 
(Hartzog et al., 1998). Based on analogy to E. coli RfaH (Belogurov et al., 2007) and on 
bacterial two-hybrid interaction assays (Nickels, 2009), the E. coli Spt5NGN domain is 
proposed to bind RNA polymerase via interaction with the loop between two antiparallel 
helices in the β’ clamp domain (the β’ clamp helices; β’ CH, residues 260–309 in E. coli RNA 
polymerase) (Mooney et al., 2009). A hydrophobic pocket on the NGN domain is the proposed 
site of β’ CH interaction (Belogurov et al., 2007). 
Surface analysis of the M. jannaschii Spt5NGN structure also revealed this 
hydrophobic pocket in the center of the protein, and this hydrophobic pocket is structurally 
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conserved in the E. coli and S. cerevisiae Spt5NGN proteins (Figure 4.7) (Mooney et al., 
2009). 
Since the E. coli Spt5NGN domain is proposed to bind RNA polymerase via interaction 
with the loop between two antiparallel helices in the β’ clamp domain (Mooney et al., 2009) it 
is proposed that M. jannaschii Spt5NGN will bind at the corresponding loop of the archaeal 
RNA polymerase. Since the structure of the M. jannaschii RNA polymerase is unknown, we 
used the structure from the archaea Sulfolobus shibatae to indicate the putative binding site of 
M. jannaschii Spt5 (Figure 4.8). This proposal however, remains to be tested experimentally. 
 
 
Figure 4.7 Surface representation of the Spt4/5 core structures from the indicated species.  
The hydrophobic residues defining the pocket are colored yellow. Spt5NGN domains are in red 
and Spt4 is in wheat. The hydrophobic residues from S. cerevisiae and from E. coli are selected 
according to (Mooney et al., 2009). 
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Figure 4.8 Structure of the archaeal RNA polymerase. 
The structure of the Sulfolobus shibatae RNA polymerase (pdb-code 2WAQ) (Korkhin et al., 
2009) is shown as a ribbon representation. The loop corresponding to the loop between two 
antiparallel helices in the β’ clamp domain in E. coli RNA polymerase is highlighted in red. 
 
4.3 Conclusion 
 
Even though quite some structural information was available from Spt4/5 core complexes we 
present the first structure of a genuine Spt4/5 heterodimer. The Spt5NGN domain consists of 
a four-stranded antiparallel beta sheet flanked by three alpha helices. Spt4 has four beta 
strands in its center, with an alpha helix at the edge of the sheet. Spt4 contains a zinc finger, 
formed by four conserved cysteine residues and is located at the opposite side of the beta 
sheet. It is likely that the zinc finger is an essential structural element of Spt4. Spt4 and 
Spt4/5 binding location 
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Spt5NGN interact via hydrophobic interfaces that are held in register by polar interactions and 
alignment of their β sheets. 
The Spt5NGN domain is conserved in archaea, bacteria and eukaryotes both 
structurally and functionally. This implies that Spt5 also shares similar mechanisms of 
transcription regulation. Spt4 reveals conservation between archaea and eukaryotes both 
structurally and functionally, there is no Spt4 homolog in bacteria. Surface analysis of the M. 
jannaschii Spt5NGN structure revealed a hydrophobic pocket in the center of the protein. This 
hydrophobic pocket is structurally conserved in the E. coli and S. cerevisiae Spt5NGN 
proteins and is suggested to bind RNA polymerase via interaction with the loop between two 
antiparallel helices in the β’ clamp domain. This work will be implemented within the work from 
Dr. Finn Werner (University College London). 
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5 Material & Methods 
 
5.1 Purification of RNA polymerase II 
 
5.1.1 Fermentation of yeast 
 
Two types of fermenters were available for producing up to 2.0 kg of yeast pellet per batch. 
The small fermenter (ISF200, Infors) has a nominal volume of 20 l and is ideally run with up to 
15 l of media. The large fermenter (ABEC, Infors) has a nominal volume of 200 l and can be 
filled with up to 160 l of media. Table 5.1 shows the media composition and the culture 
parameters of both fermenters: 
 
Table 5.1 Conditions for the fermentation of yeast 
 small fermenter (20 l) large fermenter (200 l) 
YPD media 300 g peptone 3200 g peptone 
 300 g glucose 3200 g glucose 
 222 g yeast extract 2370 g yeast extract 
 15 l desalted water 160 l desalted water 
Antibiotics1 0.75 g ampicillin 8.0 g ampicillin 
 0.15 g tetracycline⋅HCl 1.6 g tetracycline⋅HCl 
typical inoculation volume 0.3 l with OD600 ≈ 2  4-5 l with OD600 ≈ 2 
air flow 8 l/min 20 l/min 
stirrer speed 800 rpm 200 rpm 
typical growth time 12 – 15 hours 12 – 15 hours 
1added after sterilization, prior to inoculation 
 
Yeast was harvested at late logarithmic/early stationary phase, monitored by OD600 
measurement. Cells were collected by a continuous flow centrifuge (Padberg Z4IG, 20,000 
rpm). The cell pellet was resuspended in 330 ml of 3x freezing buffer (see chapter 5.1.2.1) per 
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kg cells and stirred at 4 °C for 30 min, before shock-freezing in liquid nitrogen. Cells were 
stored at -80°C until use. 
 
5.1.2 Purification of 10-subunit core RNA polymerase II 
 
Core RNA polymerase II was isolated from the Saccharomyces cerevisiae strain 
CB010ΔRpb4 (MATa pep4::HIS3/prb1::LEU2, prc1::HISG, can1, ade2, trp1) (Edwards et 
al,1990; Fu et al, 1999). This strain carries knockouts of several cellular proteases and of 
Rpb4. In the absence of Rpb4, Rpb7 dissociates from core Pol II during purification, giving 
rise to homogeneous 10-subunit core Pol II.  
 
5.1.2.1 Buffers used for the purification 
 
100 x protease inhibitor mix (p.i.) 
1.42 mg Leupeptin 
6.85 mg Pepstatin A 
850 mg PMSF 
1650 mg benzamidine 
dry ethanol to 50 ml 
stored at –20 °C; added immediately before use 
 
3x freezing buffer 
150 mM Tris-HCl, pH 7.9 @ 4 °C 
3 mM EDTA 
30 % glycerol 
30 μM ZnCl2 
3 % DMSO 
30 mM DTT 
3 x protease inhibitor mix 
 
1 x HSB150 buffer 
50 mM Tris-HCl, pH 7.9 @ 4 °C 
150 mM KCl 
1 mM EDTA 
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10 % glycerol 
10 μM ZnCl2 
10 mM DTT 
1 x protease inhibitor mix 
 
1 x HSB600 buffer 
50 mM Tris-HCl, pH 7.9 @ 4 °C 
600 mM KCl 
1 mM EDTA 
10 % glycerol 
10 μM ZnCl2 
10 mM DTT 
1 x protease inhibitor mix 
 
TEZ buffer 
50 mM Tris-HCl, pH 7.5 @ 20 °C 
1 mM EDTA 
10 μM ZnCl2 
1 mM DTT 
1 x protease inhibitor mix 
 
1 x Pol II buffer 
5 mM Hepes pH 7.25 @ 20 °C 
40 mM ammonium sulfate 
10 μM ZnCl2 
10 mM DTT 
 
Acetate buffer 
100 mM sodium acetate pH 4.0 
500 mM sodium chloride 
 
PBS 
4.3 mM Na2HPO4 
1.4 mM KH2PO4 
137 mM sodium chloride 
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2.7 mM potassium chloride 
pH 7.4 
 
Coupling buffer 
100 mM sodium bicarbonate pH 8.3 
500 mM sodium chloride 
 
5.1.2.2 Purification of core RNA Polymerase II 
 
Day1 
 
For three bead-beaters (BioSpec), up to 600 ml of cell suspension were thawed in warm 
water. Each bead-beater was filled with 200 ml of borosilicate glass beads (0.45-0.50 mm 
diameter), 1 ml of protease inhibitor mix and 200 ml of the cell suspension. HSB150 was 
added to fill the bead-beater completely, taking care to avoid any remaining air bubbles. Lysis 
was achieved within 60-75 min of bead-beating (30 s on/90 s off) while the beater chambers 
were submersed in a salt/ice mixture. Glass beads were removed by filtration through a mesh 
funnel. The beads were washed with HSB150 until the flowthrough was clear. The lysate was 
cleared by two rounds of centrifugation (45 min at 9000 rpm in a GS3 rotor or 30 min at 12000 
rpm in a SLA1500 rotor). Lipids were then removed by filtration of the supernatant through two 
layers of paper filter discs underneath a dressing cloth. The cleared lysate was applied onto a 
column packed with 250 ml of Heparin Sepharose 6 FF (GE Healthcare) (flow rate: 6-8 
ml/min), pre-equilibrated with 750 ml of HSB150. Elution was accomplished with 500 ml of 
HSB600 (flow rate: 6-8 ml/min). Proteins in the eluate were precipitated by adding 291 g of 
fine-ground ammonium sulphate per litre of eluate (= 50 % saturation), followed by 60 min of 
stirring at 4 °C, over-night incubation at 4 °C and finally centrifugation (45 min. at 12000 rpm in 
a SLA1500 rotor). The heparin column was restored by washing with 1 l of 6 M urea, followed 
by water, and stored in 5 mM potassium acetate in 20 % (v/v) ethanol. Every five runs, the 
heparin column was regenerated by a brief wash with 500 ml of 0.1 M NaOH, followed by 
water and 5 mM potassium acetate in 20 % (v/v) ethanol. 
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Day 2 
 
The next day the ammonium sulphate pellet of day 1 was dissolved in 50 ml of buffer 
TEZ. More TEZ was added to adjust the conductivity below the conductivity of TEZ containing 
additionally 400mM ammonium sulphate (TEZ400). This sample was centrifuged (15 min at 
14000 rpm in an SLA1500 rotor) to remove undissolved constituents and then loaded by 
gravity flow onto the immunoaffinity column at 4 °C (see chapter 5.1.2.3, flow rate: 0.5-1.0 
ml/min). The column was pre-equilibrated with 20 ml of TEZ containing 250 mM ammonium 
sulphate (TEZ250). The flowthrough was loaded onto a second column to increase the yield of 
Pol II. The columns were brought to room temperature, washed with 25 ml of TEZ500 at room 
temperature and Pol II was eluted in 1 ml fractions with TEZ500 containing additionally 50 % 
(v/v) glycerol (ca. 15 ml). Directly afterwards, 9 mM DTT was added to the elution fractions 
containing Pol II (monitored with the Bradford assay), and they were stored at 4 °C over night. 
The columns were washed with 5 ml of TEZ500 containing 70 % (v/v) ethylene glycol but no 
DTT, and reequilibrated with 25 ml of TEZ250 containing 0.02 % sodium azide. Generally, the 
recovery of Pol II decreased with each use of the column starting already from the first use. 
One reason is probably the sensitivity of the antibody towards DTT.  
 
Day 3 
 
The next day the peak fractions were combined and a buffer exchange procedure was 
performed. The buffer in the antibody column elution fractions was exchanged for 1x Pol II 
buffer using centrifugal ultrafiltration devices (MWCO 100,000 Da, Millipore Amicon Ultra-15). 
Completeness of the buffer exchange was monitored by measuring the conductivity of the 
flowthrough. Finally, Pol II was concentrated to 1-2 mg/ml. The Pol II sample was divided into 
aliquots of 100-500 μg Pol II. The aliquots were mixed with 1.13 times the volume of a 
saturated ammonium sulphate solution. The mixture was incubated for at least one hour at 
4 °C and centrifuged for 45 min. at 4 °C in a table-top centrifuge at 13000 rpm. Most of the 
supernatant was decanted so that the pellet was still covered with supernatant, before it was 
shock-frozen in liquid nitrogen and stored at –80 °C. Pol II stored this way is stable for at least 
3 months. From 600 g yeast pellet, a yield of 0.5-4 mg of highly purified Pol II was achieved. 
The yield was very dependent of the amount of times the immunoaffinity columns had been 
used before.  
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5.1.2.3  Preparation of Pol II immunoaffinity resin 
 
The monoclonal antibody 8WG16 (NeoClone, Madison/USA), described in (Thompson & 
Burgess, 1996) is specific for the unphosphorylated CTD of Pol II and optimized to release Pol 
II upon treatment with glycerol or ethylene glycol at room temperature (“polyol responsive 
antibody“). The antibodies were purified from mouse ascites and immobilized on activated 
chromatography media according to the following procedure: 
Lyophilized ascites were dissolved in PBS to its original volume and filtered through 
0.2 µm membrane filters. The solution was passed > 3 times through a protein-A sepharose 
column (5 ml column volume, Sigma), pre-equilibrated in PBS. The column was washed with 
50 ml PBS and antibodies were eluted with 20 ml of 0.75 M acetic acid. Fractions of 1 ml were 
collected into tubes containing 200 µl of 2 M Hepes (pH 7.9) to neutralize the acid. Peak 
fractions were pooled and the protein-A sepharose column was regenerated by washing for 5 
minutes with 1 M acetic acid, followed by PBS with 0.02 % sodium azide.  
The matrix for immunoaffinity columns was cyanogen bromide (CNBr)-activated 
sepharose 4B (Sigma), which reacts with free amines, e.g. accessible -NH2 groups on 
proteins. Care was taken to avoid other sources of free amines (e.g. Tris) and to use a sealed 
bottle of activated sepharose. For each immunoaffinity column, 5 ml of gel was prepared by 
suspending 1.43 g of CNBr-sepharose in several ml of 1 mM HCl in a disposable gravity-flow 
column. The suspended CNBr-sepharose was first washed with 100 ml of 1 mM HCl, then 
with 20 ml of coupling buffer. Coupling was performed with 10 mg of purified antibodies per 
column for 2 hours at 20 °C or over night at 4 °C. When the coupling reaction was completed, 
no protein was detectable in the supernatant. The column was then washed with 25 ml of 1 M 
Tris, pH 8 and incubated for 2 hours at room temperature or over night at 4 °C. Finally, the 
column was washed with 20 ml of coupling buffer, followed by acetate buffer and coupling 
buffer. Columns were stored at 4 °C in TEZ60 with 0.02 % sodium azide. The columns could 
be used several times, if DTT exposure was reduced to a minimum, but in general a decrease 
in Pol II yield was observed already after the first use with further decrease after subsequent 
uses. 
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5.1.3 Purification of His-tagged RNA polymerase II 
 
Ni buffer 
20 mM Tris-HCl pH 7.9 
150 mM KCl 
10 μM ZnCl2 
10% v/v glycerol 
10 mM DTT 
1x p.i. (see chapter 5.1.2.1) 
 
High salt buffer 
20 mM Tris-HCl pH 7.9 
1000 mM KCl 
7 mM imidazole 
10 μM ZnCl2 
10% v/v glycerol 
10 mM DTT 
1x p.i. (see chapter 5.1.2.1) 
 
Ni7 buffer 
20 mM Tris-HCl pH 7.9 
150 mM KCl 
7 mM imidazole 
10 μM ZnCl2 
10 mM DTT 
1x p.i. (see chapter 5.1.2.1) 
 
Elution buffer 
20 mM Tris-HCl pH 7.9 
150 mM KCl 
100 mM imidazole 
10 μM ZnCl2 
10 mM DTT 
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MonoQ buffer 
20 mM Tris-acetate pH 7.9 
0.5 mM EDTA 
10 μM ZnCl2 
10% v/v glycerol 
10 mM DTT 
 
For two bead-beaters (BioSpec), up to 400 ml of cell suspension were thawed in warm water. 
Each bead-beater was filled with 200 ml of borosilicate glass beads (0.45-0.50 mm diameter), 
1 ml of protease inhibitor mix (see chapter 5.1.2.1) and 200 ml of the cell suspension. HSB150 
(see chapter 5.1.2.1) was added to fill the bead-beater completely, taking care to avoid any 
remaining air bubbles. Lysis was achieved by bead beating for 80 min using intervals of 30 
seconds followed by 90 second pauses while the beater chambers were submersed in a 
salt/ice mixture. Glass beads were removed by filtration through a mesh funnel. The beads 
were washed with HSB150 until the flowthrough was clear. The lysate was cleared by two 
rounds of centrifugation (2x45 min at 9000 rpm in a GS3 rotor). The lysate was 
ultracentrifugated for 90 min at 4 °C (76,221 xg (24,000 rpm in SW-28 (Beckmann-Coulter), 
swing-out rotor, or 125,171 xg (40,000 rpm in Ti- 45 (Beckmann-Coulter), fixed-angle rotor). 
The fat layer was aspired from the top of the tubes and the aqueous phase was collected 
without disturbing the DNA pellet. To the lysate ammonium sulphate was added to 50% 
saturation, proteins were allowed to precipitate overnight. 
The next day, the precipitated lysate was centrifuged (45 min at 23,761 xg, 12,500 rpm 
in SLA-1500 rotor, Sorvall), and the ammonium sulphate pellet was dissolved in Ni buffer. To 
the solution 2 x 8 ml fresh Ni-NTA was added and stirred for at least 60 min. The Ni-NTA 
solution was loaded on two columns using gravity flow. After washing with high salt buffer and 
with Ni7 buffer, the protein was eluted with elution buffer. The eluted protein was 2x diluted 
with MonoQ buffer, filtered (0.22 µm), and subjected to anion exchange chromatography 
(MonoQ, GE healthcare) using a gradient from 150 mM to 1500 mM KOAc overnight.  
The next day the last elution peak (at a conductivity of 50 mS/cm) was collected and 
concentrated to 1-2 mg/ml using centrifugal ultrafiltration devices (MWCO 100,000 Da, 
Millipore Amicon Ultra-15). The Pol II sample was divided into aliquots of 100-500 μg Pol II. 
The aliquots were mixed with 1.13 times the volume of a saturated ammonium sulfate 
solution. The mixture was incubated for at least 60 min at 4 °C and centrifuged for 45 min at 
4 °C in a table-top centrifuge at 13000 rpm. Most of the supernatant was decanted so that the 
pellet was still covered with supernatant, before it was shock-frozen in liquid nitrogen and 
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stored at –80 °C. Pol II stored this way is stable for at least 3 months. From 300 g yeast pellet, 
a yield of 3-7 mg of highly purified Pol II was achieved.  
 
5.2 Purification of Rpb4/7  
 
Buffer 1 
150 mM NaCl 
5 % (v/v) glycerol 
50 mM Tris pH 7.5 
10 mM β-mercaptoethanol 
1x p.i. (see chapter 5.1.2.1) 
 
Buffer 2 
50 mM Tris pH 7.5 
5 mM DTT 
1 mM EDTA 
 
Recombinant yeast Rpb4/7 was expressed in E. coli BL21(DE3) RIL (Stratagene) using a 
bicistronic vector (Armache et al., 2005; Sakurai et al., 1999). Cells were grown in 2 x 2 L of 
culture in auto-induction medium (Studier, 2005). After approx. 4 h, when OD600 ≈ 0.6 was 
reached, the temperature was shifted from 30 °C to 20 °C. After 11 h, the cells were harvested 
by centrifugation (15 min at 5000 rpm in a SLC6000 rotor), resuspended in buffer 1 and lysed 
by means of a French Press. The lysate was cleared by centrifugation (30 min at 15000 rpm 
in a SS34 rotor) and applied onto a NiNTA column (Quiagen; 1 ml column volume). The 
column was washed subsequently with 3 ml of buffer 1, 3 ml buffer 1 containing additionally 
10 mM imidazole and 3 ml of buffer 1 containing additionally 20 mM imidazole. Elution was 
performed subsequently with 3 ml of buffer 1 containing additionally 50 mM imidazole and 3 
ml of buffer 1 containing additionally 200 mM imidazole. Peak fractions were pooled, diluted 
1:3 with buffer 2 and applied on a ResourceQ column (GE Healthcare, 6 ml column volume), 
pre-equilibrated in buffer 2. Rpb4/7 was eluted with a linear gradient from 0-1000 mM NaCl in 
buffer 2. Peak fractions were concentrated and applied on a Superose12 10/300 GL gel 
filtration column (GE Healthcare), pre-equilibrated in Pol II buffer (see chapter 5.1.2.1). The 
purified Rpb4/7 heterodimer was concentrated to 10 mg/ml and aliquots were stored at –80°C. 
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5.3 Purification of TFIIS 
 
Buffer A 
50 mM Hepes pH 7.5 
300 mM NaCl 
5% glycerol 
10 μM ZnCl2 
1x p.i. (see chapter 5.1.2.1) 
10 mM ß-mercaptoethanol 
 
For the expression of full-length TFIIS, transformed BL21(DE3) RIL (Stratagene) cells were 
used. Cells were grown in LB medium, supplemented with chloramphenicol (30 mg/l) and 
kanamycin (30 mg/l), to an OD600 of 0.7 and cooled down to 20 °C before expression was 
induced with 1mM IPTG, and continued over night. Cells from 1 l of culture were lysed by 
sonication in 50 ml of buffer A. The lysate was cleared by centrifugation (45 min, 13000 rpm, 
SS34 rotor) and was applied to a His Trap HP column (1 ml; GE Healthcare). The column was 
washed with buffer A containing 500 mM NaCl, and the protein was eluted over a total of 20 
ml with a gradient of 0 mM to 500 mM imidazole in buffer A containing 500 mM NaCl. Peak 
fractions were diluted 5-fold in buffer A and loaded onto a Mono-S 5/5HR anion exchange 
column (GE Healthcare), pre-equilibrated with buffer A containing 100 mM NaCl. The TFIIS 
variant was eluted over a total of 15 column volumes with a gradient of 100-500 mM NaCl in 
buffer A. Peak fractions were pooled and subsequently applied onto a Superose 12 10/300GL 
gel filtration column (GE Healthcare), previously equilibrated in 1 x transcription buffer 
(chapter 5.6). Elution fractions (2 mg/ml protein) were shock-frozen in liquid nitrogen and 
stored at –80°C. 
 
5.4 Purification of core Spt4/5. 
 
The core Spt4/5 from Methanocaldococcus jannaschii was purified both using normal LB 
medium (in cooperation with the group of Finn Werner at University College London) and also 
using minimal medium with selenomethionine instead of normal methionine. Below the 
purification with selenomethionine is described. The LB medium purification was performed 
the same, except that LB medium was used throughout the entire purification. 
 
Material & Methods 74 
 
Lysis buffer 
20 mM Tris-HCl pH 7.9  
300 mM potassium acetate 
7 mM magnesium acetate 
1 mM EDTA 
0.1 mM ZnCl2 
10 mM DTT 
10% glycerol 
 
Crystallization buffer 
150 mM NaCl 
25 mM Tris/HCl pH 7.5 
100 µM ZnCl2 
 
Day 1 
 
On the first day methionine auxotroph competent cells were used to transform a pGEX 
plasmid containing the core Spt4/5 from Methanococcus jannaschii. The complete Spt4 and 
the first 82 residues of Spt5 were present on the plasmid. Spt5 was cloned with an N-terminal 
GST-tag, after cleavage a GSRRASVGSH linker remains on the N-terminal Spt5. The plasmid 
was provided by the Finn laboratory from University College London. 
 
Day 2 
 
The next day a colony was picked and used for a 50 ml overnight culture in LB medium (37°C, 
with ampicillin).  
 
Day 3 
 
The next morning 30 ml of the overnight culture was used to inoculate 2.5l of LB, 
supplemented with ampicillin. Cells were grown at 37°C until OD600 was around 0.6. Cells 
were collected (5000 rpm for 10 min using a SLC6000 rotor). Cells were resuspended in 
minimal media containing selenomethionine. Cells were grown at 20°C, when the OD 
increased by 0.2, 1µM IPTG was added. Cells were grown overnight (at least 16 hours). 
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Day 4 
 
Cells were collected (5000 rpm for 15 min using a SLC6000 rotor). The pellet was dissolved in 
lysis buffer (~10ml/l) and 200 units benzonase was added. Cells were sonicated until they 
were lysed properly. The cell debrid was removed by centrifugation (20,000 rpm for 20 min 
using a sorvall SS34 rotor). The supernatant was filtered through a 0.22 µm filter and applied 
to a 5 ml GSTRAP FF column (GE healthcare). The column was washed with lysis buffer, and 
the protein was eluted using a 10 ml gradient from 0 mM to 10 mM reduced glutathione. Peak 
fractions were collected. The GS tag was cleaved by the addition of 2 µl Thrombin stock 
solution (1U/µl in PBS) per ml elution incubated for one hour at 37 °C or overnight at 4°C.  
 
Day 5 
 
The next day a sample was loaded on an SDS-PAGE gel to verify cleavage of the tag. 
Thrombin, GST and other impurities were removed by incubating at 70°C for 30 min, followed 
by centrifugation. The supernatant was filtered and applied to a Superose 12 10/300GL gel 
filtration column (GE Healthcare) (concentrated if necessary) using crystallization buffer. The 
protein fractions were collected and concentrated to 30 mg/ml. Aliquots (50-100µl) were 
shock-frozen in liquid nitrogen and stored at –80°C. 
 
5.5 Crystallization of core Spt4/5 
 
The purified core Spt4/5 from Methanocaldococcus jannaschii was concentrated to 30 mg/ml 
and crystallization screens were performed using the crystallization facility (MPI, Martinsried). 
Screens were performed at 4 °C and 20 °C as indicated in Table 5.2. 
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Table 5.2: Screens used for crystallization of the Spt4/5 core complex.  
Screens Magic1 and Magic2 are screens from the E. Conti crystallization facility (MPI 
Martinsried). The other screens are commercially available screens. 
 Hits at 20°C Hits at 4°C 
Magic 1 C1, B3, D9, G3, H1 C1, D1, D2 
Magic 2 F3 B3, H6 
Nextal Classic H2 F11 
Hampton Index E10 C3, E10, F10 
Wizard Screen B4, B9, F12 Not performed 
Cations No hits Not performed 
Anions No hits Not performed 
 
 
 
Figure 5.1 Selected hits for crystal optimization. 
From left to right: Magic 1, C1 (50 mM MES pH 6.0 30% PEG 3350), Magic 2, B3 (50 mM MES pH 
6.0 25% PEG400), Hampton Index, E10 (0.1 M Bis-Tris pH 6.5 45% v/v PPG400).  
 
  
C1 B3 E10 
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Table 5.3: Optimized crystallization conditions. 
Crystallization 
condition 
Solution1 Solution2 Crystals 
PEG3350 50 mM MES  
pH 5.5-7.0 
12-32% PEG3350 Thin, star like, 
intergrown crystals 
PEG400 50 mM MES  
pH 5.5-7.0 
20-30% PEG400 Thin, plate like 
intergrown crystals 
PPG400 100 mM Bis-Tris  
pH 5.5-7.0 
16-26% PPG400 Thin, large single 
crystals 
 
The most promising looking hits are shown in Figure 5.1. These conditions were optimized by 
hand. Crystals were grown at 22 °C with the hanging drop vapour diffusion method by mixing 
1 µl of sample solution with 1 µl of reservoir solution (optimized crystallization conditions 
shown in Table 5.3). Crystals were harvested in mother solution after 2-4 days, when they had 
reached their maximum size (approx. 0.3 x 0.3 x 0.01 mm). Crystals were transferred to 
mother solution containing additionally 25 % glycerol (only for the PEG3350 containing 
crystallization conditions). Crystals were flash-cooled by plunging into liquid nitrogen. Large 
single crystals were obtained for the PPG400 containing crystallization condition, as shown in 
Figure 5.2. All crystals obtained were very thin, resulting in difficult to handle crystals, and also 
difficult to process data sets, which were often not 100% complete. 
 
 
Figure 5.2 Crystals of the Spt4/5 core complex in a loop. 
The crystal shown was large, but thin (around 500 x 500 x 10 µm). Diffraction was reasonable in 
one direction, but not in the thin part, this was a general problem. 
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Diffraction data were collected in 0.1°-0.25° increments at the protein crystallography 
beamline X06SA of the Swiss Light Source using a Pilatus 6M pixel detector (Broennimann et 
al., 2006). Raw data were processed with XDS (Kabsch, 1993). Several attempts were made 
to solve the structure using molecular replacement, when this was unsuccessful attempts 
were made to solve the structure using heavy metals. Unfortunately the anomalous signal 
from the internal zinc was too low; therefore heavy metal soaking was tried. The compounds 
mersalyl acid, sodium tetrachloroaurate and potassium bromide were used, these attempts 
failed because the heavy metal signals were too weak and/or incomplete. Then the structure 
of the core Spt5 from Methanocaldococcus jannaschii was published. Using this structure 
only, molecular replacement still failed. However, using the M. jannaschii Spt5 structure 
together with a Spt4 homologous structure (1RYQ, 46% sequence identity), molecular 
replacement was succesfull. The 1RYQ pdb file was used with trimmed side chains, only if the 
sequence was identical to the M. jannaschii Spt4 the side chain was kept, the program Phaser 
(McCoy et al., 2005) was used for molecular replacement. The structure was build and refined 
using the programs Coot (Emsley and Cowtan, 2004) and Refmac (Vagin et al., 2004). 
 
5.6 Assembly of Pol II elongation complexes 
 
TE buffer 
10 mM Tris pH 7.4 
1 mM EDTA 
 
Assembly buffer 
50 mM Hepes pH 7.5 
40 mM (NH4)2SO4 
10 µM ZnCl2 
5 % (v/v) glyerol 
10 mM DTT 
 
Pol II buffer 
5 mM Hepes pH 7.25 at 20 °C 
40 mM (NH4)2SO4 
10 µM ZnCl2 
10 mM DTT 
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Transcription buffer 
20 mM Hepes pH 7.6 
60 mM (NH4)2SO4 
8 mM MgSO4 
10 µM ZnCl2 
10 % (v/v) glycerol 
10 mM DTT 
 
Nucleic acid scaffolds were annealed by mixing equimolar amounts of synthetic template 
DNA, nontemplate DNA, and RNA in TE buffer at a final concentration of 100 µM, heating the 
mixture to 95 °C for 5 min, and slow-cooling to 4 °C in a thermocycler. Stoichiometric Pol II 
ECs were assembled by incubating core Pol II for 10 min with 2 molar equivalents of nucleic 
acid scaffold, followed by 20 min incubation with 5 molar equivalents of recombinant Rpb4/7 in 
assembly buffer at 20 °C. The complexes were purified by size exclusion chromatography 
(Superose 6 10/300 GL) in Pol II buffer.  
For the bead-based assays, the ECs containing complete complementary scaffolds 
were assembled essentially as described (Kireeva et al., 2003)). Briefly, the DNA nontemplate 
was 5’ end-labeled with Biotin with the use of a TTTTT linker. The RNA was 5’ end-labeled 
with 6-carboxyfluoresceine (FAM). For EC assembly, RNA polymerase II was incubated with a 
hybrid of the DNA template strand annealed to the RNA (2-fold excess) in transcription buffer 
for 15 min at 20 °C, subsequently with the biotinylated nontemplate DNA strand (4-fold 
excess) for 10 min at 25 °C, and then with recombinant Rpb4/7 (5-fold excess) for 10 min at 
25 °C. 
 
5.7 RNA extension and cleavage assays 
 
Transcription buffer 
20 mM Hepes pH 7.6 
60 mM (NH4)2SO4 
8 mM MgSO4 
10 µM ZnCl2 
10 % (v/v) glycerol 
10 mM DTT 
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Loading buffer 
90 % (v/v) formamide 
50 mM EDTA pH 7.4 
 
Breaking buffer 
50 mM Tris/HCl pH 8.0 
150 mM NaCl 
0.1% (w/v) triton X-100 
5% (w/v) glycerol 
0.5 mM DTT 
 
Blocking buffer 
50 mM Tris/HCl pH 8.0 
150 mM NaCl 
2 mM EDTA pH 8.0 
0.1% (w/v) triton X-100 
5% (w/v) glycerol 
0.5% (w/v) BSA 
200 μg/ml insulin 
0.1 mg/ml heparin 
0.5 mM DTT 
 
5.7.1 Extension and cleavage assays using minimal scaffolds 
 
Stoichiometric ECs of complete Pol II, containing the 10-subunit core and Rpb4/7, were 
assembled and purified as described in chapter 5.6. The RNAs used for extension assays 
were identical to those used for structural studies, except for five additional nucleotides (5’-
UGCAU-3’) and a fluorescent linker (6-Carboxyfluorescein) at the 5’ end. For transcript 
extension, ECs were incubated with NTPs at 28 °C in transcription buffer. Reactions were 
stopped by incubating with an equal volume of gel loading buffer for 5 min at 95 °C. The RNA 
products were separated by denaturing gel electrophoresis (0.5 pmol RNA per lane, 0.4 mm 
20 % polyacrylamide gels containing 7 M urea, 50-55 °C) and visualized with a Typhoon 9400 
scanner (GE Healthcare). 
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5.7.2 MALDI-TOF analysis of minimal scaffold assays 
 
For MALDI-TOF analysis, RNA extension was performed as described in chapter 5.7.1, 
except that the reactions were stopped by the addition of an equal volume of 100 mM EDTA. 
Samples were slowly heated to 95 °C, and incubated for 5 min at 95 °C. After centrifugation 
(15 min, 13,000 rpm), the supernatant was loaded twice on a C18 ZipTip (Millipore, pre-
equilibrated with 3x 80% acetonitril, followed by 4x 100 mM TEAA) to desalt the nucleic acids, 
after washing 3x with 100 mM TEAA and 4x with H2O, nucleic acids were eluted with 80% 
acetonitril. The nucleic acids were subjected to MALDI-TOF analysis using 3-hydroxypicolinic 
acid (3-HPA) and pyrazinecarboxylic acid (PCA) (4:1) as a matrix (Zhou et al., 2004). 
 
5.7.3 Bead based extension assays 
 
For bead based extension assays, beads (Dynabeads MyOneTM Streptavidin T1 from 
Invitrogen) were washed with breaking buffer and incubated overnight with blocking buffer at 
4 °C. Assembly was performed as described in chapter 5.6. Beads were added to the 
assembled ECs and incubated for 30 min at 25 °C. Beads were subsequently washed with 
transcription buffer containing 0.1% Triton-X, transcription buffer containing 0.2 M (NH4)2SO4, 
and with transcription buffer. Beads were resuspended in transcription buffer. For RNA 
extension assays, different amounts of NTPs were added, the mixture was incubated at 28 °C 
and reactions were stopped at different time points by addition of an equal volume of 100 mM 
EDTA, essentially as described (Brueckner et al., 2007). For cleavage assays, the bead-
coupled ECs were incubated at 28 °C in transcription buffer for 5 min and stopped as 
described above. The beads were transferred into urea loading buffer, samples were heated 
to 95 °C and loaded on a 20% polyacrylamid gel containing 7 M Urea. The FAM 5’ labeled 
RNA products were visualized with a Typhoon 9400 scanner (GE Healthcare). Gel bands 
were quantified using ImageQuant (GE healthcare). For MALDI-TOF analysis, the reaction 
was incubated, stopped and analyzed as described in chapter 5.7.2. 
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5.8 Crystallization set-up 
 
NH4-Mg-acetate crystallization solution (= Natrix #38) 
50 mM Hepes pH 7.0 
140-200 mM ammonium-acetate 
150 mM magnesium-acetate 
3.5-5.5 % (v/v) PEG 6000 
5 mM TCEP 
for cryocooling additionally 20-22 % glycerol 
 
NH4-Na-acetate crystallization solution (= Natrix #38woMg) 
50 mM Hepes pH 7.0 
140-200 mM ammonium-acetate 
300 mM sodium-acetate 
4.0-6.0 % (v/v) PEG 6000 
5 mM TCEP 
for cryocooling additionally 20-22 % glycerol 
 
Purified Pol II ECs were concentrated to 3.5-4.5 mg/ml and an additional amount of the 
nucleic acid scaffold was added prior to crystallization to a final concentration of 2 µM. 
Crystals were grown at 22 °C with the hanging drop vapour diffusion method by mixing 2 µl of 
sample solution with 1 µl of reservoir solution (NH4-Mg-acetate crystallization solution). 
Crystals were harvested in mother solution after 10-20 days, when they had reached their 
maximum size (approx. 0.4 x 0.3 x 0.2 mm). Crystals were transferred stepwise over 5 hours 
to mother solution containing additionally 0-22 % glycerol. Crystals were slowly cooled to 8 °C 
and flash-cooled by plunging into liquid nitrogen. 
 For 8-oxoguanine containing crystals, the NH4-Na-acetate crystallization solution was 
used, which did not contain magnesium. Under both crystallization conditions (with or without 
magnesium) Pol II crystallizes well. There are however differences, whether the scaffold is 
pre- or posttranslocated (or if it is a mixture, see (Brueckner and Cramer, 2008)) might depend 
on the crystallization condition used. 
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5.9 Crystal structure analysis 
 
Diffraction data were collected in 0.25° increments at the protein crystallography beamline 
X06SA of the Swiss Light Source using the new Pilatus 6M pixel detector (Broennimann et al., 
2006). Raw data were processed with XDS (Kabsch, 1993). Structures were solved by 
molecular replacement with the program Phaser (McCoy et al., 2005), using the structure of 
the complete 12-subunit Pol II elongation complex without nucleic acids as a search model 
(PDB 1Y1W, (Kettenberger et al., 2004)). The molecular replacement solution was subjected 
to rigid body refinement with CNS version 1.2 (Brunger et al., 1998). Model building was 
carried out with programs Coot (Emsley and Cowtan, 2004), and Moloc (Gerber and Muller, 
1995). The nucleic acids were built into the initial Fo-Fc electron density map. The register of 
the 8oxoG containing nucleic acids was unambiguously defined by bromine labeling. A 
thymine residue in the template strand was replaced for 5-bromouracil, diffraction data of the 
resulting complex were recorded at the wavelength of the bromine K absorption edge, and the 
resulting anomalous difference Fourier maps revealed single peaks demarking the positions of 
the bromine atom (Figure 3.5b). The register of the cisplatin containing nucleic acids was 
clearly defined by the platinum atom itself. The DNA lesions (cisplatin and 8oxoG) were 
manually built into the initial Fo-Fc maps and further adjusted manually and by restrained real 
space refinement using Moloc. Atomic positions and B-factors were refined with CNS version 
1.2. Refinement was monitored with the free R factor, calculated from the same 2 % set of 
excluded reflections as in refinement of complete Pol II (Armache et al., 2005) and the 
complete Pol II EC (Brueckner et al., 2007; Kettenberger et al., 2004). Figures were prepared 
with Pymol (DeLano, 2002). 
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6 Conclusion 
 
This thesis described the study on the molecular mechanisms of Pol II encountering DNA 
damages. The damages investigated were the anticancer drug cisplatin, which forms 1,2-
d(GpG) DNA intrastrand cross-links (cisplatin lesions) and 8-oxoguanine (8oxoG), the major 
DNA lesion resulting from oxidative stress.  
We performed a structure-function analysis of Pol II stalling at a cisplatin lesion in the 
DNA template. Pol II stalling results from a translocation barrier that prevents delivery of the 
lesion to the active site. AMP misincorporation occurs at the barrier and also at an abasic site, 
suggesting that it arises from nontemplated synthesis according to an ‘A-rule’ known for DNA 
polymerases. Pol II can bypass a cisplatin lesion that is artificially placed beyond the 
translocation barrier, even in the presence of a G-A mismatch. Thus, the barrier prevents 
transcriptional mutagenesis.  
In addition, we combined structural and functional data to derive the molecular 
mechanism of Pol II transcription over 8oxoG. When Pol II encounters 8oxoG in the DNA 
template strand, it correctly incorporates cytosine in most instances, but it also 
misincorporates adenine. The misincorporated adenine forms a Hoogsteen base pair with 
8oxoG at the active center. This misincorporation requires rotation of the 8oxoG base from the 
standard anti- to an uncommon syn-conformation, which likely occurs during 8oxoG loading 
into the active site at a lower rate. X-ray analysis showed that the misincorporated adenine 
forms a Hoogsteen base pair with 8oxoG in the polymerase active center. Mass spectrometric 
analysis of RNA extension products showed that the misincorporated adenine escapes the 
intrinsic proofreading function of Pol II, and remains in the RNA product after polymerase 
bypass, resulting in transcriptional mutagenesis. Mutagenesis is suppressed by the transcript 
cleavage-stimulatory factor TFIIS, which is essential for cell survival during oxidative stress. 
We showed that the stalling mechanism at a cisplatin lesion differs from that of Pol II 
stalling at a photolesion, which involves delivery of the lesion to the active site and lesion-
templated misincorporation that blocks transcription. In case of 8oxoG no stalling occurs at all, 
which leads to transcriptional mutagenesis. Together, these results lead to the conclusion that 
it is impossible to predict the mechanisms of transcriptional stalling or mutagenesis at other 
types of lesions. 
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7 Abbreviations 
 
8oxoG  8-oxoguanine 
AD  Activation domain 
AMP   adenosine monophosphate 
ATP   adenosine triphosphate 
CPD   cyclobutane pyrimidine dimer 
CTD   C-terminal domain of Rpb1 of Pol II 
CTP   cytosine triphosphate 
DBD  DNA binding domain 
DNA   deoxyribonucleic acid 
DPE   downstream promoter element 
DSIF  DRB sensitivity-inducing factor 
DTT  dithiothreitol 
E. coli   Escherichia coli 
EC   elongation complex 
EDTA   ethylene diamine tetraacetic acid 
EM   electron microscopy 
GMP   guanosine monophosphate 
GTF   general transcription factor 
GTP   guanosine triphosphate 
Hepes   4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
Inr   initiator element 
IPTG   isopropyl β-D-1-thiogalactopyranoside 
MALDI  matrix-assisted laser desorption ionization 
MALDI-TOF matrix-assisted laser desorption ionization with time-of-flight analysator mass 
spectrometry 
Min  minutes 
mRNA  messenger RNA 
MWCO  molecular weight cutoff 
NTP   nucleotide triphosphate 
PDB   protein data bank 
PEG   polyethylene glycol (number indicates average molecular weight in Da) 
PIC   preinitiation complex 
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Pol   eukaryotic DNA-dependent RNA polymerase 
PPG  polypropylene glycol 
RMSD  root mean square deviation 
RNA  ribonucleic acid 
Rpb   subunit of Pol II (=RNA polymerase B) 
S. cerevisiae  Saccharomyces cerevisiae 
Spt  Suppressor of Ty 
TAF   TBP-associated factor 
TBP   TATA binding protein 
TCEP  tris(2-carboxyethyl)phosphine 
TCR   transcription coupled repair 
TFII   transcription factor of Pol II transcription 
Tris   trishydroxymethylaminomethane 
UMP  uridine monophosphate 
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